label	i	c	o	span
gold	Brand-name desogestrel 	Generic desogestrel 	Plasma concentration	Plasma concentration-time curves of 3-ketodesogestrel are shown in Figure 1, exhibiting the evident similarity of the plasma level profiles of both formulations.
c	3 - ketodesogestrel	3 - ketodesogestrel	plasma level	Plasma concentration-time curves of 3-ketodesogestrel are shown in Figure 1, exhibiting the evident similarity of the plasma level profiles of both formulations.
gold	Brand-name desogestrel 	Generic desogestrel 	Plasma concentration	Plasma concentration-time curves of 3-ketodesogestrel are shown in Figure 1, exhibiting the evident similarity of the plasma level profiles of both formulations.
c	3 - ketodesogestrel	3 - ketodesogestrel	Plasma concentration - time curves	Plasma concentration-time curves of 3-ketodesogestrel are shown in Figure 1, exhibiting the evident similarity of the plasma level profiles of both formulations.
gold	plant extract St. John's Wort (SJW)	placebo	E-selectin, metalloproteinase-9 (MMP-9), Granulocyte colony-stimulating factor (G-CSF) , and Vascular endothelial growth factor (VEGF)	There were no clinical or biomarker benefit of SJW versus placebo in RP.
x	placebo	SJW	clinical or biomarker benefit	There were no clinical or biomarker benefit of SJW versus placebo in RP.
gold	undergo a tubal resection after Pomeroy ligation	undergo a tubal resection after bipolar coagulation with Kleppinger forceps	Postoperative pain at 6 hours	Pain at incision sites or in the pelvis was described by the patient as being usually mild or moderate 6 hours postoperatively (mean score: 4.6 out of 10 for ligation, 4.0 of 10 for coagulation) except in 6 patients (ligation 4, coagulation 2) that required overnight admission for parenteral morphine or meperidine.
c	parenteral morphine or meperidine .	parenteral morphine or meperidine .	Pain at incision sites or in the pelvis	Pain at incision sites or in the pelvis was described by the patient as being usually mild or moderate 6 hours postoperatively (mean score: 4.6 out of 10 for ligation, 4.0 of 10 for coagulation) except in 6 patients (ligation 4, coagulation 2) that required overnight admission for parenteral morphine or meperidine.
gold	Simvastatine	Placebo	Progression-free survival	The median PFS was 5.9 months (95% CI, 4.5–7.3) in the XELIRI/FOLFIRI plus simvastatin group and 7.0 months (95% CI, 5.4–8.6) in the XELIRI/FOLFIRI plus placebo group (P=0.937).
x	XELIRI / FOLFIRI plus simvastatin	XELIRI / FOLFIRI plus placebo	median PFS	The median PFS was 5.9 months (95% CI, 4.5–7.3) in the XELIRI/FOLFIRI plus simvastatin group and 7.0 months (95% CI, 5.4–8.6) in the XELIRI/FOLFIRI plus placebo group (P=0.937).
gold	Simvastatine	Placebo	Overall survival	No significant difference was observed between the two groups with respect to OS (median, 15.9 months (simvastatin) vs 19.9 months (placebo), P=0.826).
x	simvastatin	placebo	OS	No significant difference was observed between the two groups with respect to OS (median, 15.9 months (simvastatin) vs 19.9 months (placebo), P=0.826).
gold	Simvastatine	Placebo	Time to progression 	No significant differences were observed between the simvastatin and placebo groups regarding two of the secondary end points, OS and TTP.
x	simvastatin	placebo	OS and TTP .	No significant differences were observed between the simvastatin and placebo groups regarding two of the secondary end points, OS and TTP.
gold	Simvastatine	Placebo	Toxicity 	The addition of simvastatin did not result in any clinically significant increase in treatment-related toxicities
c	simvastatin	simvastatin	treatment - related toxicities .	The addition of simvastatin did not result in any clinically significant increase in treatment-related toxicities.
gold	TOMOX	FOLFOX4	Hepatic disorders and asthenia	Hepatic disorders (25.0 vs. 14.3 %) and asthenia (19.6 vs. 11.0 %) had a numerically higher incidence in the TOMOX group than the FOLFOX4 group, but the differences did not reach statistical significance.
x	TOMOX	FOLFOX4	asthenia	Hepatic disorders (25.0 vs. 14.3 %) and asthenia (19.6 vs. 11.0 %) had a numerically higher incidence in the TOMOX group than the FOLFOX4 group, but the differences did not reach statistical significance.
gold	TOMOX	FOLFOX4	Hepatic disorders and asthenia	Hepatic disorders (25.0 vs. 14.3 %) and asthenia (19.6 vs. 11.0 %) had a numerically higher incidence in the TOMOX group than the FOLFOX4 group, but the differences did not reach statistical significance.
x	TOMOX	FOLFOX4	Hepatic disorders	Hepatic disorders (25.0 vs. 14.3 %) and asthenia (19.6 vs. 11.0 %) had a numerically higher incidence in the TOMOX group than the FOLFOX4 group, but the differences did not reach statistical significance.
gold	TOMOX	FOLFOX4	Hepatic disorders and asthenia	hepatic disorders and asthenia were higher in TOMOX group (p = ns).
i	TOMOX	FOLFOX4	Grades 3 and 4 neutropenia	Grades 3 and 4 neutropenia (p < 0.0001) and leukopenia (p = 0.028) were more common with the FOLFOX4 regimen, while hepatic disorders and asthenia were higher in TOMOX group (p = ns).
gold	TOMOX	FOLFOX4	Hepatic disorders and asthenia	hepatic disorders and asthenia were higher in TOMOX group (p = ns).
i	TOMOX	FOLFOX4	hepatic disorders and asthenia	Grades 3 and 4 neutropenia (p < 0.0001) and leukopenia (p = 0.028) were more common with the FOLFOX4 regimen, while hepatic disorders and asthenia were higher in TOMOX group (p = ns).
gold	TOMOX	FOLFOX4	Hepatic disorders and asthenia	hepatic disorders and asthenia were higher in TOMOX group (p = ns).
c	FOLFOX4	FOLFOX	leukopenia	Grades 3 and 4 neutropenia (p < 0.0001) and leukopenia (p = 0.028) were more common with the FOLFOX4 regimen, while hepatic disorders and asthenia were higher in TOMOX group (p = ns).
gold	~1100 kJ/d of hazelnuts	chocolate	Plasma total cholesterol	Plasma total cholesterol in the hazelnut group was lower compared to the chocolate group (P = 0.006), with a tendency for the hazelnut group to be lower than the control (P  = 0.057).
c	hazelnut	Dairy milk chocolate	Plasma total cholesterol	Plasma total cholesterol in the hazelnut group was lower compared to the chocolate group (P = 0.006), with a tendency for the hazelnut group to be lower than the control (P  = 0.057).
gold	epoetin-α	control	mean hemoglobin level at admission at the discharge	the discharge hemoglobin level was higher in the epoetin-α group (10.6 g/dL versus 9.69 g/dL) (P < 0.001).
c	epoetin - α	Epoetin - α	discharge hemoglobin level	At admission, the mean hemoglobin level was higher in the epoetin-α group (13.8 g/dL versus 12.2 g/dL) (P = 0.001); the discharge hemoglobin level was higher in the epoetin-α group (10.6 g/dL versus 9.69 g/dL) (P < 0.001).
gold	epoetin-α	control	mean hemoglobin level at admission at the discharge	the discharge hemoglobin level was higher in the epoetin-α group (10.6 g/dL versus 9.69 g/dL) (P < 0.001).
c	epoetin - α	Epoetin - α	mean hemoglobin level	At admission, the mean hemoglobin level was higher in the epoetin-α group (13.8 g/dL versus 12.2 g/dL) (P = 0.001); the discharge hemoglobin level was higher in the epoetin-α group (10.6 g/dL versus 9.69 g/dL) (P < 0.001).
gold	epoetin-α	control	mean duration of surgery	There was no difference in mean duration of surgery between cohorts (epoetin-α versus control: 85.4 minutes versus 92.66 minutes) (P = 0.276) (Table 2).
c	epoetin - α	Epoetin - α	mean duration of surgery	There was no difference in mean duration of surgery between cohorts (epoetin-α versus control: 85.4 minutes versus 92.66 minutes) (P = 0.276) (Table 2).
gold	epoetin-α	control	hospital stay	The epoetin-α cohort had a shorter hospital stay (3 versus 3.67, P = 0.042) (Table 2).
c	epoetin - α	Epoetin - α	hospital stay	The epoetin-α cohort had a shorter hospital stay (3 versus 3.67, P = 0.042) (Table 2).
gold	Ketamine	Control	Usage of analgesics	Small dose of ketamine does not seem to be a useful adjunct to anesthetic and does not decrease the consumption of anesthetic during surgery.
c	ketamine	Ketamine	consumption of anesthetic	Small dose of ketamine does not seem to be a useful adjunct to anesthetic and does not decrease the consumption of anesthetic during surgery.
gold	Aripiprazole	Placbeo	Parent-rated Aberrant Behavior Checklis improvement	Aripiprazole produced a significant improvement in the mean parent/caregiver-rated Aberrant Behavior Checklist Japanese Version irritability subscale score relative to placebo from week 3 through week 8
x	Aripiprazole	placebo	mean parent / caregiver - rated Aberrant Behavior Checklist Japanese Version irritability subscale score	Aripiprazole produced a significant improvement in the mean parent/caregiver-rated Aberrant Behavior Checklist Japanese Version irritability subscale score relative to placebo from week 3 through week 8.
gold	Aripiprazole	Placbeo	Clinician-rated Clinical Global Impression-Improvement scores	At week 8, aripiprazole group showed a statistically significant improvement in mean clinician-rated CGI-I scores greater than the placebo group [2.7 (0.1) vs 3.4 (0.1); TD: −0.62 (95% CI: −1.02 to − 0.22); p = 0.003].
x	aripiprazole	placebo	mean clinician - rated CGI - I scores	At week 8, aripiprazole group showed a statistically significant improvement in mean clinician-rated CGI-I scores greater than the placebo group [2.7 (0.1) vs 3.4 (0.1); TD: −0.62 (95% CI: −1.02 to − 0.22); p = 0.003].
gold	Aripiprazole	Placbeo	Social withdrawal 	There was no significant difference between aripiprazole group and the placebo group in the mean ABC-J stereotypy, inappropriate speech and lethargy/social withdrawal subscale scores
x	aripiprazole	placebo	ABC - J response rate , CY - BOCS ( compulsion scale )	There was no significant difference between aripiprazole group and the placebo group in the mean ABC-J stereotypy, inappropriate speech and lethargy/social withdrawal subscale scores, as well as ABC-J response rate, CY-BOCS (compulsion scale) (Table 2).
gold	Aripiprazole	Placbeo	Social withdrawal 	There was no significant difference between aripiprazole group and the placebo group in the mean ABC-J stereotypy, inappropriate speech and lethargy/social withdrawal subscale scores
x	aripiprazole	placebo	mean ABC - J stereotypy , inappropriate speech and lethargy / social withdrawal subscale scores	There was no significant difference between aripiprazole group and the placebo group in the mean ABC-J stereotypy, inappropriate speech and lethargy/social withdrawal subscale scores, as well as ABC-J response rate, CY-BOCS (compulsion scale) (Table 2).
gold	Aripiprazole	Placbeo	Serious adverse effects	All patients randomized to aripiprazole completed the study, and no serious adverse events were reported.
c	aripiprazole	Aripiprazole	serious adverse events	All patients randomized to aripiprazole completed the study, and no serious adverse events were reported.
gold	Mitomycine C	Acetic acid	Involvement with granulation tissue in the mastoid cavity at the third phase of treatment	In the third phase of treatment of topical MMC only 7 patients (28%) had involvement with granulation tissue in the mastoid cavity and this is less than 25% involvement but the percentage of patients in acetic acid group that involved in more than 25% mastoid involvement was 17 patients (68%), which was again statistically signi- ficant (P<0.05).
x	acetic acid	topical MMC	involvement with granulation tissue in the mastoid cavity	In the third phase of treatment of topical MMC only 7 patients (28%) had involvement with granulation tissue in the mastoid cavity and this is less than 25% involvement but the percentage of patients in acetic acid group that involved in more than 25% mastoid involvement was 17 patients (68%), which was again statistically signi- ficant (P<0.05).
gold	Mitomycine C	Acetic acid	Involvement with granulation tissue in the mastoid cavity at the third phase of treatment	In the third phase of treatment of topical MMC only 7 patients (28%) had involvement with granulation tissue in the mastoid cavity and this is less than 25% involvement but the percentage of patients in acetic acid group that involved in more than 25% mastoid involvement was 17 patients (68%), which was again statistically signi- ficant (P<0.05).
x	acetic acid	topical MMC	mastoid involvement	In the third phase of treatment of topical MMC only 7 patients (28%) had involvement with granulation tissue in the mastoid cavity and this is less than 25% involvement but the percentage of patients in acetic acid group that involved in more than 25% mastoid involvement was 17 patients (68%), which was again statistically signi- ficant (P<0.05).
gold	Mitomycine C	Acetic acid	Dry cavity after 3 months of treatment	After three months of follow up, the final result of using topical MMC and acetic acid was evaluated and the incidence of dry cavity with no granulation tissue was 92% in MMC group whereas it was 24% in Acid group, which was statistically significant (P<0.05).
x	MMC	acetic acid	incidence of dry cavity with no granulation tissue	After three months of follow up, the final result of using topical MMC and acetic acid was evaluated and the incidence of dry cavity with no granulation tissue was 92% in MMC group whereas it was 24% in Acid group, which was statistically significant (P<0.05).
gold	Mitomycine C	Acetic acid	Dry cavity after 3 months of treatment	After three months of follow up, the final result of using topical MMC and acetic acid was evaluated and the incidence of dry cavity with no granulation tissue was 92% in MMC group whereas it was 24% in Acid group, which was statistically significant (P<0.05).
x	MMC	Acid	incidence of dry cavity with no granulation tissue	After three months of follow up, the final result of using topical MMC and acetic acid was evaluated and the incidence of dry cavity with no granulation tissue was 92% in MMC group whereas it was 24% in Acid group, which was statistically significant (P<0.05).
gold	Mitomycine C	Acetic acid	Dry cavity after 3 months of treatment	After three months of follow up, the final result of using topical MMC and acetic acid was evaluated and the incidence of dry cavity with no granulation tissue was 92% in MMC group whereas it was 24% in Acid group, which was statistically significant (P<0.05).
x	acetic acid	Acid	incidence of dry cavity with no granulation tissue	After three months of follow up, the final result of using topical MMC and acetic acid was evaluated and the incidence of dry cavity with no granulation tissue was 92% in MMC group whereas it was 24% in Acid group, which was statistically significant (P<0.05).
gold	Mitomycine C	Acetic acid	Patients with 25% involvement with granulation tissue in the mastoid cavity after three months	At the same time the percentage of patients with 25% involvement mastoid cavity with granulation was 8% in the MMC group (two patients) and 19 patients (76%) in Acid group, which was again statistically significant difference.
x	MMC	Acid	percentage of patients with 25 % involvement mastoid cavity with granulation	At the same time the percentage of patients with 25% involvement mastoid cavity with granulation was 8% in the MMC group (two patients) and 19 patients (76%) in Acid group, which was again statistically significant difference.
gold	Mitomycine C	Acetic acid	Dry cavity after 1 month of treatment	But one month later, this percentage (complete dry mastoid) in the MMC group was 72% and for Acid group was 20% that was statistically significant (P<0.05).
c	Acid	topical MMC	percentage ( complete dry mastoid )	But one month later, this percentage (complete dry mastoid) in the MMC group was 72% and for Acid group was 20% that was statistically significant (P<0.05).
gold	Radiofrequency ablation	Hepatic resection	Rate of complications	More patients developed complications with resection compared to RFA (59% compared to 43%), but the difference was not statistically significant.
x	RFA	resection	complications	More patients developed complications with resection compared to RFA (59% compared to 43%), but the difference was not statistically significant.
gold	Radiofrequency ablation	Hepatic resection	Local recurrence rate through the study	Over the course of the study (mean follow-up of 46 months for patients undergoing RFA), 60% of patients who had only open RFA suffered local recurrences compared to 7% of patients who underwent hepatic resection (P < .0005).
x	hepatic resection	RFA	local recurrences	Over the course of the study (mean follow-up of 46 months for patients undergoing RFA), 60% of patients who had only open RFA suffered local recurrences compared to 7% of patients who underwent hepatic resection (P < .0005).
gold	Radiofrequency ablation	Hepatic resection	Duration of surgery	The operative time was significantly longer for the resection group compared to the RFA group (median of 269 minutes (range 118 to 452) versus 204 minutes (range 113 to 316); P < .0005).
c	RFA	hepatic resection , RFA	operative time	The operative time was significantly longer for the resection group compared to the RFA group (median of 269 minutes (range 118 to 452) versus 204 minutes (range 113 to 316); P < .0005).
gold	Radiofrequency ablation	Hepatic resection	Need for ICU 	Rates of ICU admission (6.5% of patients overall), and length of stay (median of 7 days for all patients; range 1 to 48) were not significantly different between patients having hepatic resection and RFA.
c	hepatic resection	hepatic resection , RFA	length of stay	Rates of ICU admission (6.5% of patients overall), and length of stay (median of 7 days for all patients; range 1 to 48) were not significantly different between patients having hepatic resection and RFA.
gold	Radiofrequency ablation	Hepatic resection	Need for ICU 	Rates of ICU admission (6.5% of patients overall), and length of stay (median of 7 days for all patients; range 1 to 48) were not significantly different between patients having hepatic resection and RFA.
c	hepatic resection	hepatic resection , RFA	Rates of ICU admission	Rates of ICU admission (6.5% of patients overall), and length of stay (median of 7 days for all patients; range 1 to 48) were not significantly different between patients having hepatic resection and RFA.
gold	Radiofrequency ablation	Hepatic resection	Disease-free survival rate at 5 years	The 5-year disease-free survival (DFS) for patients who underwent hepatic resection was 17% (95% CI = 7 to 29%), compared to 15% (95% CI = 6 to 28%) for patients who underwent RFA alone (P = .06).
c	RFA	RFA , RFA plus hepatic resection	5 - year disease - free survival ( DFS )	The 5-year disease-free survival (DFS) for patients who underwent hepatic resection was 17% (95% CI = 7 to 29%), compared to 15% (95% CI = 6 to 28%) for patients who underwent RFA alone (P = .06).
gold	Helium preconditioning (3 × 5 min of 70 % helium and 30 % oxygen) was applied before aortic cross clamping; postconditioning (15 min of helium) was applied before release of the aortic cross clamp.	no helium	Postoperative troponin T	Postoperative troponin T was 11 arbitrary units [5, 31; area-under-the-curve (interquartile range)] for controls, and no statistically significant changes were observed after helium preconditioning [He-pre: 11 (6, 18)], helium postconditioning [He-post: 11 (8, 15)], helium pre- and postconditioning [He-PP: 14 (6, 20)] and after sevoflurane preconditioning [APC: 12 (8, 24), p = 0.13].
x	helium preconditioning	helium postconditioning	Postoperative troponin T	Postoperative troponin T was 11 arbitrary units [5, 31; area-under-the-curve (interquartile range)] for controls, and no statistically significant changes were observed after helium preconditioning [He-pre: 11 (6, 18)], helium postconditioning [He-post: 11 (8, 15)], helium pre- and postconditioning [He-PP: 14 (6, 20)] and after sevoflurane preconditioning [APC: 12 (8, 24), p = 0.13].
gold	Helium preconditioning (3 × 5 min of 70 % helium and 30 % oxygen) was applied before aortic cross clamping; postconditioning (15 min of helium) was applied before release of the aortic cross clamp.	no helium	Postoperative troponin T	Postoperative troponin T was 11 arbitrary units [5, 31; area-under-the-curve (interquartile range)] for controls, and no statistically significant changes were observed after helium preconditioning [He-pre: 11 (6, 18)], helium postconditioning [He-post: 11 (8, 15)], helium pre- and postconditioning [He-PP: 14 (6, 20)] and after sevoflurane preconditioning [APC: 12 (8, 24), p = 0.13].
x	helium preconditioning	sevoflurane preconditioning	Postoperative troponin T	Postoperative troponin T was 11 arbitrary units [5, 31; area-under-the-curve (interquartile range)] for controls, and no statistically significant changes were observed after helium preconditioning [He-pre: 11 (6, 18)], helium postconditioning [He-post: 11 (8, 15)], helium pre- and postconditioning [He-PP: 14 (6, 20)] and after sevoflurane preconditioning [APC: 12 (8, 24), p = 0.13].
gold	Helium preconditioning (3 × 5 min of 70 % helium and 30 % oxygen) was applied before aortic cross clamping; postconditioning (15 min of helium) was applied before release of the aortic cross clamp.	no helium	Postoperative troponin T	Postoperative troponin T was 11 arbitrary units [5, 31; area-under-the-curve (interquartile range)] for controls, and no statistically significant changes were observed after helium preconditioning [He-pre: 11 (6, 18)], helium postconditioning [He-post: 11 (8, 15)], helium pre- and postconditioning [He-PP: 14 (6, 20)] and after sevoflurane preconditioning [APC: 12 (8, 24), p = 0.13].
x	helium preconditioning	helium pre - and postconditioning	Postoperative troponin T	Postoperative troponin T was 11 arbitrary units [5, 31; area-under-the-curve (interquartile range)] for controls, and no statistically significant changes were observed after helium preconditioning [He-pre: 11 (6, 18)], helium postconditioning [He-post: 11 (8, 15)], helium pre- and postconditioning [He-PP: 14 (6, 20)] and after sevoflurane preconditioning [APC: 12 (8, 24), p = 0.13].
gold	Helium preconditioning (3 × 5 min of 70 % helium and 30 % oxygen) was applied before aortic cross clamping; postconditioning (15 min of helium) was applied before release of the aortic cross clamp.	no helium	Postoperative troponin T	Postoperative troponin T was 11 arbitrary units [5, 31; area-under-the-curve (interquartile range)] for controls, and no statistically significant changes were observed after helium preconditioning [He-pre: 11 (6, 18)], helium postconditioning [He-post: 11 (8, 15)], helium pre- and postconditioning [He-PP: 14 (6, 20)] and after sevoflurane preconditioning [APC: 12 (8, 24), p = 0.13].
x	helium postconditioning	sevoflurane preconditioning	Postoperative troponin T	Postoperative troponin T was 11 arbitrary units [5, 31; area-under-the-curve (interquartile range)] for controls, and no statistically significant changes were observed after helium preconditioning [He-pre: 11 (6, 18)], helium postconditioning [He-post: 11 (8, 15)], helium pre- and postconditioning [He-PP: 14 (6, 20)] and after sevoflurane preconditioning [APC: 12 (8, 24), p = 0.13].
gold	Helium preconditioning (3 × 5 min of 70 % helium and 30 % oxygen) was applied before aortic cross clamping; postconditioning (15 min of helium) was applied before release of the aortic cross clamp.	no helium	Postoperative troponin T	Postoperative troponin T was 11 arbitrary units [5, 31; area-under-the-curve (interquartile range)] for controls, and no statistically significant changes were observed after helium preconditioning [He-pre: 11 (6, 18)], helium postconditioning [He-post: 11 (8, 15)], helium pre- and postconditioning [He-PP: 14 (6, 20)] and after sevoflurane preconditioning [APC: 12 (8, 24), p = 0.13].
x	helium postconditioning	helium pre - and postconditioning	Postoperative troponin T	Postoperative troponin T was 11 arbitrary units [5, 31; area-under-the-curve (interquartile range)] for controls, and no statistically significant changes were observed after helium preconditioning [He-pre: 11 (6, 18)], helium postconditioning [He-post: 11 (8, 15)], helium pre- and postconditioning [He-PP: 14 (6, 20)] and after sevoflurane preconditioning [APC: 12 (8, 24), p = 0.13].
gold	Helium preconditioning (3 × 5 min of 70 % helium and 30 % oxygen) was applied before aortic cross clamping; postconditioning (15 min of helium) was applied before release of the aortic cross clamp.	no helium	Postoperative troponin T	Postoperative troponin T was 11 arbitrary units [5, 31; area-under-the-curve (interquartile range)] for controls, and no statistically significant changes were observed after helium preconditioning [He-pre: 11 (6, 18)], helium postconditioning [He-post: 11 (8, 15)], helium pre- and postconditioning [He-PP: 14 (6, 20)] and after sevoflurane preconditioning [APC: 12 (8, 24), p = 0.13].
x	sevoflurane preconditioning	helium pre - and postconditioning	Postoperative troponin T	Postoperative troponin T was 11 arbitrary units [5, 31; area-under-the-curve (interquartile range)] for controls, and no statistically significant changes were observed after helium preconditioning [He-pre: 11 (6, 18)], helium postconditioning [He-post: 11 (8, 15)], helium pre- and postconditioning [He-PP: 14 (6, 20)] and after sevoflurane preconditioning [APC: 12 (8, 24), p = 0.13].
gold	telemonitoring group	usual group	ER visits for all causes	Similarly, patients in the telemonitoring intervention group had fewer ER visits for all causes than those in the usual care group (0.36 vs. 0.91 per patient; p = 0.006).
x	usual care	telemonitoring intervention	ER visits	Similarly, patients in the telemonitoring intervention group had fewer ER visits for all causes than those in the usual care group (0.36 vs. 0.91 per patient; p = 0.006).
gold	telemonitoring group	usual group	the time to first re-admission for COPD exacerbation	, time to first re-admission for COPD exacerbation was significantly increased in the telemonitoring group than in the usual care group (p = 0.026).
c	usual care	telemonitoring and usual care	time to first re - admission for COPD exacerbation	During the follow-up period, time to first re-admission for COPD exacerbation was significantly increased in the telemonitoring group than in the usual care group (p = 0.026).
gold	telemonitoring group	usual group	ER visits for all causes	Telemonitoring was also associated with a reduced number of all-cause re-admissions (0.23 vs. 0.68/patient; p = 0.002) and emergency room visits (0.36 vs. 0.91/patient; p = 0.006).
c	Telemonitoring	telemonitoring	emergency room visits	Telemonitoring was also associated with a reduced number of all-cause re-admissions (0.23 vs. 0.68/patient; p = 0.002) and emergency room visits (0.36 vs. 0.91/patient; p = 0.006).
gold	telemonitoring group	usual group	ER visits for all causes	Telemonitoring was also associated with a reduced number of all-cause re-admissions (0.23 vs. 0.68/patient; p = 0.002) and emergency room visits (0.36 vs. 0.91/patient; p = 0.006).
c	Telemonitoring	telemonitoring	number of all - cause re - admissions	Telemonitoring was also associated with a reduced number of all-cause re-admissions (0.23 vs. 0.68/patient; p = 0.002) and emergency room visits (0.36 vs. 0.91/patient; p = 0.006).
gold	telemonitoring group	usual group	episodes of COPD-related re-admissions or ER visits per capita	Moreover, the telemonitoring group patients tended to have fewer episodes of COPD-related re-admissions (0.19 vs. 0.49; p = 0.11) or ER visits (0.23 vs. 0.55; p = 0.16) per capita than did usual care group patients.
c	telemonitoring	telemonitoring	episodes of COPD - related re - admissions	Moreover, the telemonitoring group patients tended to have fewer episodes of COPD-related re-admissions (0.19 vs. 0.49; p = 0.11) or ER visits (0.23 vs. 0.55; p = 0.16) per capita than did usual care group patients.
gold	telemonitoring group	usual group	episodes of COPD-related re-admissions or ER visits per capita	Moreover, the telemonitoring group patients tended to have fewer episodes of COPD-related re-admissions (0.19 vs. 0.49; p = 0.11) or ER visits (0.23 vs. 0.55; p = 0.16) per capita than did usual care group patients.
c	telemonitoring	telemonitoring	ER visits	Moreover, the telemonitoring group patients tended to have fewer episodes of COPD-related re-admissions (0.19 vs. 0.49; p = 0.11) or ER visits (0.23 vs. 0.55; p = 0.16) per capita than did usual care group patients.
gold	Oral vaccine	Placebo	Interferon γ response 	Median response for interferon γ was 232 spots per 106 cells with 1011 VP compared with 57 spots per 106 cells with placebo (p<0·0001).
x	placebo	interferon γ	Median response	Median response for interferon γ was 232 spots per 106 cells with 1011 VP compared with 57 spots per 106 cells with placebo (p<0·0001).
gold	Oral vaccine	Placebo	Diarrhoea	The cumulative frequency of abdominal pain, diarrhoea, and nasal congestion after all three vaccinations was significantly higher in vaccinees than placebo recipients (21 [16·8%] of 125 vs one [2·4%] of 41, p=0·017; 24 [19·2%] of 125 vs two [4·9%] of 41, p=0·027; 41 [32·8%] of 125 vs six [14·6%] of 41, p=0·028; respectively
c	placebo	H5N1 vaccines	cumulative frequency of abdominal pain , diarrhoea , and nasal congestion	The cumulative frequency of abdominal pain, diarrhoea, and nasal congestion after all three vaccinations was significantly higher in vaccinees than placebo recipients (21 [16·8%] of 125 vs one [2·4%] of 41, p=0·017; 24 [19·2%] of 125 vs two [4·9%] of 41, p=0·027; 41 [32·8%] of 125 vs six [14·6%] of 41, p=0·028; respectively).
gold	Oral vaccine	Placebo	Headache 	Headache was the only reactogenicity symptom reported more frequently in vaccinees than placebo recipients after the first vaccination (p=0·046; table 1)
c	placebo	Ad4 and Ad7 vaccines	Headache	Headache was the only reactogenicity symptom reported more frequently in vaccinees than placebo recipients after the first vaccination (p=0·046; table 1).
gold	Oral vaccine	Placebo	Abdominal pain	The cumulative frequency of abdominal pain, diarrhoea, and nasal congestion after all three vaccinations was significantly higher in vaccinees than placebo recipients (21 [16·8%] of 125 vs one [2·4%] of 41, p=0·017; 24 [19·2%] of 125 vs two [4·9%] of 41, p=0·027; 41 [32·8%] of 125 vs six [14·6%] of 41, p=0·028; respectively; appendix).
c	placebo	H5N1 vaccines	cumulative frequency of abdominal pain , diarrhoea , and nasal congestion	The cumulative frequency of abdominal pain, diarrhoea, and nasal congestion after all three vaccinations was significantly higher in vaccinees than placebo recipients (21 [16·8%] of 125 vs one [2·4%] of 41, p=0·017; 24 [19·2%] of 125 vs two [4·9%] of 41, p=0·027; 41 [32·8%] of 125 vs six [14·6%] of 41, p=0·028; respectively; appendix).
gold	Oral vaccine	Placebo	Interferon γ response 	Interferon-γ T-cell response to recombinant H5 haemagglutinin protein or peptide pools ranged from 38% (nine of 24 vaccinees) with 107 VP to 70% (16 of 23 vaccines) with 1011 VP, compared with only 5% (two of 41) of placebo recipients (figure 2).
c	placebo	H5N1 vaccines	Interferon - γ T - cell response to recombinant H5 haemagglutinin protein or peptide pools	Interferon-γ T-cell response to recombinant H5 haemagglutinin protein or peptide pools ranged from 38% (nine of 24 vaccinees) with 107 VP to 70% (16 of 23 vaccines) with 1011 VP, compared with only 5% (two of 41) of placebo recipients (figure 2).
gold	furosemide	0.9% saline	breathlessness, leg discomfort, chest tightness to exercise cessation were not significantly different across treatments.	The relative contributions of breathlessness [0.9% saline, 41.9 ± 3.4%; 40 mg furosemide, 40.2 ± 3.6%; 120 mg furosemide, 39.4 ± 4.0% (p = 0.876)], leg discomfort [0.9% saline, 55.4 ± 4.1%; 40 mg furosemide, 54.4 ± 4.2%; 120 mg furosemide, 51.7 ± 4.6% (p = 0.746)] and chest tightness [0.9% saline, 2.4 ± 1.5%; 40 mg furosemide, 0.8 ± 0.8%; 120 mg furosemide, 6.0 ± 3.3% (p = 0.170)] to exercise cessation were not significantly different across treatments.
x	furosemide	saline	leg discomfort	The relative contributions of breathlessness [0.9% saline, 41.9 ± 3.4%; 40 mg furosemide, 40.2 ± 3.6%; 120 mg furosemide, 39.4 ± 4.0% (p = 0.876)], leg discomfort [0.9% saline, 55.4 ± 4.1%; 40 mg furosemide, 54.4 ± 4.2%; 120 mg furosemide, 51.7 ± 4.6% (p = 0.746)] and chest tightness [0.9% saline, 2.4 ± 1.5%; 40 mg furosemide, 0.8 ± 0.8%; 120 mg furosemide, 6.0 ± 3.3% (p = 0.170)] to exercise cessation were not significantly different across treatments.
gold	furosemide	0.9% saline	breathlessness, leg discomfort, chest tightness to exercise cessation were not significantly different across treatments.	The relative contributions of breathlessness [0.9% saline, 41.9 ± 3.4%; 40 mg furosemide, 40.2 ± 3.6%; 120 mg furosemide, 39.4 ± 4.0% (p = 0.876)], leg discomfort [0.9% saline, 55.4 ± 4.1%; 40 mg furosemide, 54.4 ± 4.2%; 120 mg furosemide, 51.7 ± 4.6% (p = 0.746)] and chest tightness [0.9% saline, 2.4 ± 1.5%; 40 mg furosemide, 0.8 ± 0.8%; 120 mg furosemide, 6.0 ± 3.3% (p = 0.170)] to exercise cessation were not significantly different across treatments.
x	furosemide	saline	breathlessness	The relative contributions of breathlessness [0.9% saline, 41.9 ± 3.4%; 40 mg furosemide, 40.2 ± 3.6%; 120 mg furosemide, 39.4 ± 4.0% (p = 0.876)], leg discomfort [0.9% saline, 55.4 ± 4.1%; 40 mg furosemide, 54.4 ± 4.2%; 120 mg furosemide, 51.7 ± 4.6% (p = 0.746)] and chest tightness [0.9% saline, 2.4 ± 1.5%; 40 mg furosemide, 0.8 ± 0.8%; 120 mg furosemide, 6.0 ± 3.3% (p = 0.170)] to exercise cessation were not significantly different across treatments.
gold	furosemide	0.9% saline	breathlessness, leg discomfort, chest tightness to exercise cessation were not significantly different across treatments.	The relative contributions of breathlessness [0.9% saline, 41.9 ± 3.4%; 40 mg furosemide, 40.2 ± 3.6%; 120 mg furosemide, 39.4 ± 4.0% (p = 0.876)], leg discomfort [0.9% saline, 55.4 ± 4.1%; 40 mg furosemide, 54.4 ± 4.2%; 120 mg furosemide, 51.7 ± 4.6% (p = 0.746)] and chest tightness [0.9% saline, 2.4 ± 1.5%; 40 mg furosemide, 0.8 ± 0.8%; 120 mg furosemide, 6.0 ± 3.3% (p = 0.170)] to exercise cessation were not significantly different across treatments.
x	furosemide	saline	chest tightness	The relative contributions of breathlessness [0.9% saline, 41.9 ± 3.4%; 40 mg furosemide, 40.2 ± 3.6%; 120 mg furosemide, 39.4 ± 4.0% (p = 0.876)], leg discomfort [0.9% saline, 55.4 ± 4.1%; 40 mg furosemide, 54.4 ± 4.2%; 120 mg furosemide, 51.7 ± 4.6% (p = 0.746)] and chest tightness [0.9% saline, 2.4 ± 1.5%; 40 mg furosemide, 0.8 ± 0.8%; 120 mg furosemide, 6.0 ± 3.3% (p = 0.170)] to exercise cessation were not significantly different across treatments.
gold	Insulin + Pramlintide (6 mcg/U)	Insulin + Pramlintide (12 mcg/U)	Elevation of glucose and glucagon after 1 hour	Compared with placebo/insulin, all three pramlintide/insulin ratios produced marked and statistically equivalent reductions of increments of glucose and glucagon in the first hour, with levels subsequently increasing.
x	pramlintide / insulin	placebo / insulin	increments of glucose and glucagon	Compared with placebo/insulin, all three pramlintide/insulin ratios produced marked and statistically equivalent reductions of increments of glucose and glucagon in the first hour, with levels subsequently increasing.
gold	Insulin + Pramlintide (all doses)	Insulin alone	Glucagon AUC 0–3 h	Reductions of AUC0–3 h for glucagon for the 6, 9 and 12 mcg/U were 57, 59 and 55% (Table 1; all doses vs placebo: p < 0.05).
x	glucagon	placebo	AUC0 – 3 h	Reductions of AUC0–3 h for glucagon for the 6, 9 and 12 mcg/U were 57, 59 and 55% (Table 1; all doses vs placebo: p < 0.05).
gold	Insulin + Pramlintide (all doses)	Insulin alone	Glucose AUC 0–3 h	The AUC0–3 h for glucose was reduced by 60, 58 and 72% for the 6, 9 and 12 mcg/U ratios (Table 1; all doses vs placebo: p < 0.001)
c	placebo	meal ‐ time and basal hormone replacement	AUC0 – 3 h for glucose	The AUC0–3 h for glucose was reduced by 60, 58 and 72% for the 6, 9 and 12 mcg/U ratios (Table 1; all doses vs placebo: p < 0.001).
gold	Insulin + Pramlintide (all doses)	Insulin alone	Hypoglycemia after 24 hours	No symptomatic hypoglycaemia occurred during the 24‐h period after pramlintide administration.
c	pramlintide	pramlintide	symptomatic hypoglycaemia	No symptomatic hypoglycaemia occurred during the 24‐h period after pramlintide administration.
gold	gutta-percha/AH26 	Resilon/RealSeal SE samples	residual antimicrobial activity of CHX at one week and at three and six weeks	The results showed that residual antimicrobial activity of CHX was significantly higher in gutta-percha/AH26 samples than in Resilon/RealSeal SE samples (P=0.02 at one week and P=0.003 at three and six weeks, respectively).
c	CHX	Resilon	residual antimicrobial activity of	The results showed that residual antimicrobial activity of CHX was significantly higher in gutta-percha/AH26 samples than in Resilon/RealSeal SE samples (P=0.02 at one week and P=0.003 at three and six weeks, respectively).
gold	lidocaine (5 mgs/kg)	placebo	intensity of pain	ntravenous lidocaine was superior regarding the reduction of the intensity of pain, the allodynia, and the hyperalgesia compared to placebo.
x	lidocaine	placebo	intensity of pain , the allodynia , and the hyperalgesia	Intravenous lidocaine was superior regarding the reduction of the intensity of pain, the allodynia, and the hyperalgesia compared to placebo.
gold	lidocaine (5 mgs/kg)	placebo	intensity of pain	Both lidocaine and placebo reduced the intensity of pain, at the end of each session; however, lidocaine achieved a greater reduction compared to placebo (76.4% versus 40.1%, P < 0.001).
x	lidocaine	placebo	intensity of pain	Both lidocaine and placebo reduced the intensity of pain, at the end of each session; however, lidocaine achieved a greater reduction compared to placebo (76.4% versus 40.1%, P < 0.001).
gold	indacaterol 150 μg o.d	placebo	forced expiratory volume in 1 s (FEV1) at Week 12	Trough FEV1 (LSM ± SEM) at Week 12 was 1.48 ± 0.018 L for indacaterol and 1.35 ± 0.019 L for placebo, a clinically relevant difference of 130 ± 24 mL (p < 0.001).
x	indacaterol	placebo	Trough FEV1	Trough FEV1 (LSM ± SEM) at Week 12 was 1.48 ± 0.018 L for indacaterol and 1.35 ± 0.019 L for placebo, a clinically relevant difference of 130 ± 24 mL (p < 0.001).
gold	indacaterol 150 μg o.d	placebo	FEV1 after one dose	Trough FEV1 after one dose was significantly higher with indacaterol than placebo (p < 0.001).
x	indacaterol	placebo	Trough FEV1	Trough FEV1 after one dose was significantly higher with indacaterol than placebo (p < 0.001).
gold	indacaterol 150 μg o.d	placebo	Standardised AUC measurements for FEV1 at Week 12	Standardised AUC measurements for FEV1 (between 5 min and 4 h, 5 min and 1 h, and 1 and 4 h post-dose) at Week 12 were all significantly greater with indacaterol than placebo (p < 0.001), with LSM (± SEM) differences of 170 ± 24, 180 ± 24, and 170 ± 24 mL, respectively.
x	indacaterol	placebo	AUC measurements for FEV1	Standardised AUC measurements for FEV1 (between 5 min and 4 h, 5 min and 1 h, and 1 and 4 h post-dose) at Week 12 were all significantly greater with indacaterol than placebo (p < 0.001), with LSM (± SEM) differences of 170 ± 24, 180 ± 24, and 170 ± 24 mL, respectively.
gold	indacaterol 150 μg o.d	placebo	The overall rate of adverse events (ASs)	The overall rates of AEs were comparable between the groups (indacaterol 49.3%, placebo 46.8%)
x	indacaterol	placebo	AEs	The overall rates of AEs were comparable between the groups (indacaterol 49.3%, placebo 46.8%), with the most common AEs being COPD worsening (indacaterol 8.5%, placebo 12.2%) and cough (indacaterol 6.2%, placebo 7.3%).
gold	indacaterol 150 μg o.d	placebo	The overall rate of adverse events (ASs)	The overall rates of AEs were comparable between the groups (indacaterol 49.3%, placebo 46.8%)
x	indacaterol	placebo	COPD worsening	The overall rates of AEs were comparable between the groups (indacaterol 49.3%, placebo 46.8%), with the most common AEs being COPD worsening (indacaterol 8.5%, placebo 12.2%) and cough (indacaterol 6.2%, placebo 7.3%).
gold	Interactive Voice Response	Questionnaire sent by post	Need for reminders	There was less need for reminders in the IVR group (p = 0.000).
c	IVR	IVR	need for reminders	There was less need for reminders in the IVR group (p = 0.000).
gold	liposome bupivacaine	bupivacaine HCl	cumulative pain	In the analysis of cumulative pain intensity scores through 72 hours, liposome bupivacaine was associated with lower pain scores than the comparator in 16 of 19 treatment arms assessed, achieving statistically significant differences compared with bupivacaine HCl (P < 0.05) in five of 17 treatment arms
x	liposome bupivacaine	bupivacaine HCl	pain scores	In the analysis of cumulative pain intensity scores through 72 hours, liposome bupivacaine was associated with lower pain scores than the comparator in 16 of 19 treatment arms assessed, achieving statistically significant differences compared with bupivacaine HCl (P < 0.05) in five of 17 treatment arms.
gold	liposome bupivacaine	bupivacaine HCl	cumulative pain	In the analysis of cumulative pain intensity scores through 72 hours, liposome bupivacaine was associated with lower pain scores than the comparator in 16 of 19 treatment arms assessed, achieving statistically significant differences compared with bupivacaine HCl (P < 0.05) in five of 17 treatment arms
x	liposome bupivacaine	bupivacaine HCl	cumulative pain intensity scores	In the analysis of cumulative pain intensity scores through 72 hours, liposome bupivacaine was associated with lower pain scores than the comparator in 16 of 19 treatment arms assessed, achieving statistically significant differences compared with bupivacaine HCl (P < 0.05) in five of 17 treatment arms.
gold	liposome bupivacaine	bupivacaine HCl and placebo	The median time to first postsurgical use of rescue opioid medication	The median time to first postsurgical use of rescue opioid medication was significantly longer with liposome bupivacaine (9.3 hours) compared with bupivacaine HCl (6.4 hours; P = 0.013) and placebo (3.6 hours; P < 0.0001).
x	bupivacaine HCl	placebo	median time to first postsurgical use of rescue opioid medication	The median time to first postsurgical use of rescue opioid medication was significantly longer with liposome bupivacaine (9.3 hours) compared with bupivacaine HCl (6.4 hours; P = 0.013) and placebo (3.6 hours; P < 0.0001).
gold	liposome bupivacaine	bupivacaine HCl and placebo	The median time to first postsurgical use of rescue opioid medication	The median time to first postsurgical use of rescue opioid medication was significantly longer with liposome bupivacaine (9.3 hours) compared with bupivacaine HCl (6.4 hours; P = 0.013) and placebo (3.6 hours; P < 0.0001).
x	liposome bupivacaine	bupivacaine HCl	median time to first postsurgical use of rescue opioid medication	The median time to first postsurgical use of rescue opioid medication was significantly longer with liposome bupivacaine (9.3 hours) compared with bupivacaine HCl (6.4 hours; P = 0.013) and placebo (3.6 hours; P < 0.0001).
gold	liposome bupivacaine	bupivacaine HCl and placebo	The median time to first postsurgical use of rescue opioid medication	The median time to first postsurgical use of rescue opioid medication was significantly longer with liposome bupivacaine (9.3 hours) compared with bupivacaine HCl (6.4 hours; P = 0.013) and placebo (3.6 hours; P < 0.0001).
x	liposome bupivacaine	placebo	median time to first postsurgical use of rescue opioid medication	The median time to first postsurgical use of rescue opioid medication was significantly longer with liposome bupivacaine (9.3 hours) compared with bupivacaine HCl (6.4 hours; P = 0.013) and placebo (3.6 hours; P < 0.0001).
gold	liposome bupivacaine 266 mg 	placebo	"satisfied� or "extremely satisfied� with their postoperative analgesia at 24 hours after surgery	At 24 hours after surgery in this study, 95% of patients in the liposome bupivacaine 266 mg group were "satisfied" or "extremely satisfied" with their postoperative analgesia compared with 72% in the placebo group (P = 0.0007)
x	placebo	liposome bupivacaine	postoperative analgesia	At 24 hours after surgery in this study, 95% of patients in the liposome bupivacaine 266 mg group were "satisfied" or "extremely satisfied" with their postoperative analgesia compared with 72% in the placebo group (P = 0.0007).
gold	liposome bupivacaine 532 mg at day 8	bupivacaine HCl 150 mg group at day 8	mean satisfaction ratings, based on an 11-point NRS (0 = completely unsatisfied; 10 = completely satisfied)	Statistically significant differences in favor of liposome bupivacaine were also observed in study 3, where mean satisfaction ratings, based on an 11-point NRS (0 = completely unsatisfied; 10 = completely satisfied), were 9.2 in the liposome bupivacaine 532 mg group and 8.3 in the bupivacaine HCl 150 mg group (P = 0.045) at day 8, and in study 4 where mean ratings in the liposome bupivacaine 266 mg and bupivacaine HCl 75 mg groups were 7.4 and 6.0, respectively (P = 0.03) at 96 hours.
x	bupivacaine HCl	liposome bupivacaine	mean satisfaction ratings	Statistically significant differences in favor of liposome bupivacaine were also observed in study 3, where mean satisfaction ratings, based on an 11-point NRS (0 = completely unsatisfied; 10 = completely satisfied), were 9.2 in the liposome bupivacaine 532 mg group and 8.3 in the bupivacaine HCl 150 mg group (P = 0.045) at day 8, and in study 4 where mean ratings in the liposome bupivacaine 266 mg and bupivacaine HCl 75 mg groups were 7.4 and 6.0, respectively (P = 0.03) at 96 hours.
gold	rifaximin followed by the probiotic VSL#3	no treatment	progression of chronic prostatitis plus IBS toward chronic microbial prostate-vesiculitis (PV) or prostate-vesiculo-epididymitis (PVE) in infertile males	Long-term treatment with rifaximin and the probiotic VSL#3 is effective in lowering the progression of prostatitis into more complicated forms of male accessory gland infections
x	rifaximin	probiotic VSL # 3	prostatitis	Long-term treatment with rifaximin and the probiotic VSL#3 is effective in lowering the progression of prostatitis into more complicated forms of male accessory gland infections in infertile patients with bacteriologically cured CBP plus IBS.
gold	Riociguat group	Placebo group	Pulmonary vascular resistance	PVR significantly decreased in the riociguat group (−29%) compared with placebo (+3%) by a least-squares (LS) mean difference of 246 dyn s/cm5 (95% CI −303 to −190; p<0.0001)
x	riociguat	placebo	PVR	PVR significantly decreased in the riociguat group (−29%) compared with placebo (+3%) by a least-squares (LS) mean difference of 246 dyn s/cm5 (95% CI −303 to −190; p<0.0001) (figure 1).
gold	crystalloid	colloid	Frequency of nausea	At 2 hours the proportion of the patients experiencing nausea (38.2 vs 17.9%, P = 0.03) (Figure 2, Panel A) and the mean nausea score (1.49 ± 0.3 vs 0.68 ± 0.2, P = 0.028) (Figure 2, Panel B) and were increased in the colloid group compared to crystalloid respectively.
c	crystalloid	colloid ( hydroxyethyl starch 130 / 0 . 4 )	patients experiencing nausea	At 2 hours the proportion of the patients experiencing nausea (38.2 vs 17.9%, P = 0.03) (Figure 2, Panel A) and the mean nausea score (1.49 ± 0.3 vs 0.68 ± 0.2, P = 0.028) (Figure 2, Panel B) and were increased in the colloid group compared to crystalloid respectively.
gold	crystalloid	colloid	Frequency of nausea	At 2 hours the proportion of the patients experiencing nausea (38.2 vs 17.9%, P = 0.03) (Figure 2, Panel A) and the mean nausea score (1.49 ± 0.3 vs 0.68 ± 0.2, P = 0.028) (Figure 2, Panel B) and were increased in the colloid group compared to crystalloid respectively.
c	crystalloid	colloid ( hydroxyethyl starch 130 / 0 . 4 )	mean nausea score	At 2 hours the proportion of the patients experiencing nausea (38.2 vs 17.9%, P = 0.03) (Figure 2, Panel A) and the mean nausea score (1.49 ± 0.3 vs 0.68 ± 0.2, P = 0.028) (Figure 2, Panel B) and were increased in the colloid group compared to crystalloid respectively.
gold	Pharmacist telephone counseling	Usual care	Adherence in patients starting with RAS-inhibitors, statins and bisphosphonates.	Comparing patients with counseling to patients with usual care (per protocol analysis), adherence was statistically significant higher for patients starting with RAS-inhibitors, statins and bisphosphonates.
x	usual care	RAS - inhibitors , statins and bisphosphonates .	adherence	Comparing patients with counseling to patients with usual care (per protocol analysis), adherence was statistically significant higher for patients starting with RAS-inhibitors, statins and bisphosphonates.
gold	Pharmacist telephone counseling	Usual care	Adherence in patients starting with antidepressants	For antidepressants we found no significant difference in adherence rate between patients in the intervention arm (62.7% SD 41.7) and patients with usual care (66.8%, 40.9).
c	usual care	intervention for antidepressants and bisphosphonates and usual care for RAS - inhibitors and statins .	adherence rate	For antidepressants we found no significant difference in adherence rate between patients in the intervention arm (62.7% SD 41.7) and patients with usual care (66.8%, 40.9).
gold	0.25 μg calcitriol per day for one year	placebo	osteoclacin (OC) and β-CrossLaps levels	No significant differences were observed between calcitriol and placebo groups for OC (37.2±11.8 ng/ml vs 25.8±7.4 ng/ml; P = 0.39) and β-CrossLaps (0.33±0.07 ng/ml vs 0.50±0.12 ng/ml; P = 0.29) (table 2).
x	calcitriol	placebo	β - CrossLaps	No significant differences were observed between calcitriol and placebo groups for OC (37.2±11.8 ng/ml vs 25.8±7.4 ng/ml; P = 0.39) and β-CrossLaps (0.33±0.07 ng/ml vs 0.50±0.12 ng/ml; P = 0.29) (table 2).
gold	0.25 μg calcitriol per day for one year	placebo	osteoclacin (OC) and β-CrossLaps levels	No significant differences were observed between calcitriol and placebo groups for OC (37.2±11.8 ng/ml vs 25.8±7.4 ng/ml; P = 0.39) and β-CrossLaps (0.33±0.07 ng/ml vs 0.50±0.12 ng/ml; P = 0.29) (table 2).
x	calcitriol	placebo	OC	No significant differences were observed between calcitriol and placebo groups for OC (37.2±11.8 ng/ml vs 25.8±7.4 ng/ml; P = 0.39) and β-CrossLaps (0.33±0.07 ng/ml vs 0.50±0.12 ng/ml; P = 0.29) (table 2).
gold	High-intensity interval training (HIIT) plus either ginger or placebo	Ginger alone	VO2max	Tukey's post hoc test revealed increased VO2max in both "exercise + ginger" (P < 0.000) and "exercise + placebo" (P < 0.000) groups, in comparison to "ginger" group.
x	exercise + placebo	ginger	VO2max	Tukey's post hoc test revealed increased VO2max in both "exercise + ginger" (P < 0.000) and "exercise + placebo" (P < 0.000) groups, in comparison to "ginger" group.
gold	High-intensity interval training (HIIT) plus either ginger or placebo	Ginger alone	VO2max	Tukey's post hoc test revealed increased VO2max in both "exercise + ginger" (P < 0.000) and "exercise + placebo" (P < 0.000) groups, in comparison to "ginger" group.
x	exercise + placebo	exercise + ginger	VO2max	Tukey's post hoc test revealed increased VO2max in both "exercise + ginger" (P < 0.000) and "exercise + placebo" (P < 0.000) groups, in comparison to "ginger" group.
gold	High-intensity interval training (HIIT) plus either ginger or placebo	Ginger alone	VO2max	Tukey's post hoc test revealed increased VO2max in both "exercise + ginger" (P < 0.000) and "exercise + placebo" (P < 0.000) groups, in comparison to "ginger" group.
x	ginger	exercise + ginger	VO2max	Tukey's post hoc test revealed increased VO2max in both "exercise + ginger" (P < 0.000) and "exercise + placebo" (P < 0.000) groups, in comparison to "ginger" group.
gold	Dual release ciprofloxacin for inhalation (DRCFI)	Placebo	Time to first pulmonary exacerbation	DRCFI treatment delayed time to first pulmonary exacerbation (median 134 vs 58 days, p=0.057 mITT, p=0.046 per protocol).
c	DRCFI	DRCFI	time to first pulmonary exacerbation	DRCFI treatment delayed time to first pulmonary exacerbation (median 134 vs 58 days, p=0.057 mITT, p=0.046 per protocol).
gold	Dual release ciprofloxacin for inhalation (DRCFI)	Placebo	Systemic adverse events	DRCFI was well tolerated with a similar incidence of systemic adverse events to the placebo group
c	placebo	DRCFI	systemic adverse events	DRCFI was well tolerated with a similar incidence of systemic adverse events to the placebo group, but fewer pulmonary adverse events.
gold	Dual release ciprofloxacin for inhalation (DRCFI)	Placebo	Systemic adverse events	DRCFI was well tolerated with a similar incidence of systemic adverse events to the placebo group
c	placebo	DRCFI	tolerated	DRCFI was well tolerated with a similar incidence of systemic adverse events to the placebo group, but fewer pulmonary adverse events.
gold	Dual release ciprofloxacin for inhalation (DRCFI)	Placebo	Systemic adverse events	DRCFI was well tolerated with a similar incidence of systemic adverse events to the placebo group
c	placebo	DRCFI	pulmonary adverse events .	DRCFI was well tolerated with a similar incidence of systemic adverse events to the placebo group, but fewer pulmonary adverse events.
gold	Dual release ciprofloxacin for inhalation (DRCFI)	Placebo	Time to first pulmonary exacerbation	The median time to pulmonary exacerbation by Kaplan–Meier analysis was 134 days for the DRCFI group and 58 days for the placebo group, although this achieved conventional statistical significance only on the per protocol population (p=0.057 mITT, p=0.046 per protocol, by log-rank test; see figure 3).
c	placebo	DRCFI )	median time to pulmonary exacerbation	The median time to pulmonary exacerbation by Kaplan–Meier analysis was 134 days for the DRCFI group and 58 days for the placebo group, although this achieved conventional statistical significance only on the per protocol population (p=0.057 mITT, p=0.046 per protocol, by log-rank test; see figure 3).
gold	Dual release ciprofloxacin for inhalation (DRCFI)	Placebo	FEV1, SGRQ total score, and 6MWT distance	No significant differences were seen between the two treatment groups for changes to day 28 for other outcome measures including FEV1 (DRCFI −0.05±0.12 vs placebo 0.00±0.10 L, p=0.18), SGRQ total score (DRCFI −1.3±7.16 vs placebo −6.4±9.8, p=0.08) or 6MWT distance (DRCFI 0.6±71.6 vs placebo −7.6±92.3 m, p=0.54).
c	placebo	aminoglycosides	FEV1	No significant differences were seen between the two treatment groups for changes to day 28 for other outcome measures including FEV1 (DRCFI −0.05±0.12 vs placebo 0.00±0.10 L, p=0.18), SGRQ total score (DRCFI −1.3±7.16 vs placebo −6.4±9.8, p=0.08) or 6MWT distance (DRCFI 0.6±71.6 vs placebo −7.6±92.3 m, p=0.54).
gold	Dual release ciprofloxacin for inhalation (DRCFI)	Placebo	FEV1, SGRQ total score, and 6MWT distance	No significant differences were seen between the two treatment groups for changes to day 28 for other outcome measures including FEV1 (DRCFI −0.05±0.12 vs placebo 0.00±0.10 L, p=0.18), SGRQ total score (DRCFI −1.3±7.16 vs placebo −6.4±9.8, p=0.08) or 6MWT distance (DRCFI 0.6±71.6 vs placebo −7.6±92.3 m, p=0.54).
c	placebo	Inhaled corticosteroids	6MWT distance	No significant differences were seen between the two treatment groups for changes to day 28 for other outcome measures including FEV1 (DRCFI −0.05±0.12 vs placebo 0.00±0.10 L, p=0.18), SGRQ total score (DRCFI −1.3±7.16 vs placebo −6.4±9.8, p=0.08) or 6MWT distance (DRCFI 0.6±71.6 vs placebo −7.6±92.3 m, p=0.54).
gold	Dual release ciprofloxacin for inhalation (DRCFI)	Placebo	FEV1, SGRQ total score, and 6MWT distance	No significant differences were seen between the two treatment groups for changes to day 28 for other outcome measures including FEV1 (DRCFI −0.05±0.12 vs placebo 0.00±0.10 L, p=0.18), SGRQ total score (DRCFI −1.3±7.16 vs placebo −6.4±9.8, p=0.08) or 6MWT distance (DRCFI 0.6±71.6 vs placebo −7.6±92.3 m, p=0.54).
c	placebo	aminoglycoside antibiotics	SGRQ total score	No significant differences were seen between the two treatment groups for changes to day 28 for other outcome measures including FEV1 (DRCFI −0.05±0.12 vs placebo 0.00±0.10 L, p=0.18), SGRQ total score (DRCFI −1.3±7.16 vs placebo −6.4±9.8, p=0.08) or 6MWT distance (DRCFI 0.6±71.6 vs placebo −7.6±92.3 m, p=0.54).
gold	oral marine protein supplement (MPS)	placebo	mean number of terminal hairs	MPS-treated subjects achieved a significant increase in the number of terminal hairs within the target area (P < 0.0001) which was significantly greater than placebo (P < 0.0001).
x	MPS	placebo	number of terminal hairs within the target area	MPS-treated subjects achieved a significant increase in the number of terminal hairs within the target area (P < 0.0001) which was significantly greater than placebo (P < 0.0001).
gold	oral marine protein supplement (MPS)	placebo	total scores on the Quality of Life Questionnaire	MPS use also resulted in significantly less hair shedding (P = 0.002) and higher total Self-Assessment (P = 0.006) and Quality of Life Questionnaires scores (P = 0.035).
c	MPS	MPS	hair shedding	MPS use also resulted in significantly less hair shedding (P = 0.002) and higher total Self-Assessment (P = 0.006) and Quality of Life Questionnaires scores (P = 0.035).
gold	oral marine protein supplement (MPS)	placebo	total scores on the Quality of Life Questionnaire	MPS use also resulted in significantly less hair shedding (P = 0.002) and higher total Self-Assessment (P = 0.006) and Quality of Life Questionnaires scores (P = 0.035).
c	MPS	MPS	total Self - Assessment	MPS use also resulted in significantly less hair shedding (P = 0.002) and higher total Self-Assessment (P = 0.006) and Quality of Life Questionnaires scores (P = 0.035).
gold	oral marine protein supplement (MPS)	placebo	total scores on the Quality of Life Questionnaire	MPS use also resulted in significantly less hair shedding (P = 0.002) and higher total Self-Assessment (P = 0.006) and Quality of Life Questionnaires scores (P = 0.035).
c	MPS	MPS	Quality of Life Questionnaires scores	MPS use also resulted in significantly less hair shedding (P = 0.002) and higher total Self-Assessment (P = 0.006) and Quality of Life Questionnaires scores (P = 0.035).
gold	Tailored letters	Practitioner-delivered brief advice	24-hour point prevalence abstinence	the tailored letters intervention was significantly more effective than brief advice for 24-hour [odds ratio (OR) = 1.4; P = 0.047] but not for 7-day point prevalence abstinence (OR = 1.4; P = 0.068) for prolonged abstinence, or for alternative assumptions about participants lost to follow-up.
c	tailored letters intervention	computer - tailored letters and physician - delivered brief advice	point prevalence abstinence	Using complete case analysis, the tailored letters intervention was significantly more effective than brief advice for 24-hour [odds ratio (OR) = 1.4; P = 0.047] but not for 7-day point prevalence abstinence (OR = 1.4; P = 0.068) for prolonged abstinence, or for alternative assumptions about participants lost to follow-up.
gold	evacetrapib (10–600 mg)	placebo	Apolipoprotein B-100 (apo B)	At the highest dose (600 mg), evacetrapib significantly inhibited CETP activity (91%), increased HDL-C (87%) and apo AI (42%), and decreased LDL-C (29%) and apo B (26%) relative to placebo.
x	placebo	evacetrapib	apo B	At the highest dose (600 mg), evacetrapib significantly inhibited CETP activity (91%), increased HDL-C (87%) and apo AI (42%), and decreased LDL-C (29%) and apo B (26%) relative to placebo.
gold	evacetrapib (10–600 mg)	placebo	Apolipoprotein B-100 (apo B)	At the highest dose (600 mg), evacetrapib significantly inhibited CETP activity (91%), increased HDL-C (87%) and apo AI (42%), and decreased LDL-C (29%) and apo B (26%) relative to placebo.
x	placebo	evacetrapib	CETP activity	At the highest dose (600 mg), evacetrapib significantly inhibited CETP activity (91%), increased HDL-C (87%) and apo AI (42%), and decreased LDL-C (29%) and apo B (26%) relative to placebo.
gold	evacetrapib (10–600 mg)	placebo	Apolipoprotein B-100 (apo B)	At the highest dose (600 mg), evacetrapib significantly inhibited CETP activity (91%), increased HDL-C (87%) and apo AI (42%), and decreased LDL-C (29%) and apo B (26%) relative to placebo.
x	placebo	evacetrapib	LDL - C	At the highest dose (600 mg), evacetrapib significantly inhibited CETP activity (91%), increased HDL-C (87%) and apo AI (42%), and decreased LDL-C (29%) and apo B (26%) relative to placebo.
gold	evacetrapib (10–600 mg)	placebo	Apolipoprotein B-100 (apo B)	At the highest dose (600 mg), evacetrapib significantly inhibited CETP activity (91%), increased HDL-C (87%) and apo AI (42%), and decreased LDL-C (29%) and apo B (26%) relative to placebo.
x	placebo	evacetrapib	HDL - C	At the highest dose (600 mg), evacetrapib significantly inhibited CETP activity (91%), increased HDL-C (87%) and apo AI (42%), and decreased LDL-C (29%) and apo B (26%) relative to placebo.
gold	evacetrapib (10–600 mg)	placebo	Apolipoprotein B-100 (apo B)	At the highest dose (600 mg), evacetrapib significantly inhibited CETP activity (91%), increased HDL-C (87%) and apo AI (42%), and decreased LDL-C (29%) and apo B (26%) relative to placebo.
x	placebo	evacetrapib	apo AI	At the highest dose (600 mg), evacetrapib significantly inhibited CETP activity (91%), increased HDL-C (87%) and apo AI (42%), and decreased LDL-C (29%) and apo B (26%) relative to placebo.
gold	evacetrapib (10–600 mg)	placebo	high-density lipoprotein-cholesterol (HDL-C)	At the highest dose tested (600 mg), evacetrapib increased HDL-C by 86.8% (P < 0.001 vs placebo)
x	placebo	evacetrapib	LDL	At the highest dose tested (600 mg), evacetrapib increased HDL-C by 86.8% (P < 0.001 vs placebo) and decreased LDL by 28.6% (P < 0.001 vs placebo) from baseline to Day 14.
gold	evacetrapib (10–600 mg)	placebo	high-density lipoprotein-cholesterol (HDL-C)	At the highest dose tested (600 mg), evacetrapib increased HDL-C by 86.8% (P < 0.001 vs placebo)
x	placebo	evacetrapib	HDL - C	At the highest dose tested (600 mg), evacetrapib increased HDL-C by 86.8% (P < 0.001 vs placebo) and decreased LDL by 28.6% (P < 0.001 vs placebo) from baseline to Day 14.
gold	evacetrapib (10–600 mg)	placebo	systolic blood pressure (SBP) and diastolic blood pressure (DBP)	No significant differences in either SBP or DBP were observed with evacetrapib 600 mg compared with placebo (Table 3).
x	placebo	evacetrapib	SBP or DBP	No significant differences in either SBP or DBP were observed with evacetrapib 600 mg compared with placebo (Table 3).
gold	evacetrapib (10–600 mg)	placebo	Apolipoprotein AI (apo AI)	The increase in apo AI and decreases in apo B and ratio of apo B to apo AI were significant at all dose levels of evacetrapib.
c	evacetrapib	Evacetrapib	apo AI and decreases in apo B and ratio of apo B to apo AI	The increase in apo AI and decreases in apo B and ratio of apo B to apo AI were significant at all dose levels of evacetrapib.
gold	Uracil-tegafur and leucovorin	Control	Recurrence-free survival	UFT/LV significantly prolonged the RFS compared with surgery alone with the hazard ratio of 0.56 (95% confidence interval, 0.38–0.83; P = 0.003)
c	UFT / LV	surgery alone	RFS	UFT/LV significantly prolonged the RFS compared with surgery alone with the hazard ratio of 0.56 (95% confidence interval, 0.38–0.83; P = 0.003).
gold	Uracil-tegafur and leucovorin	Control	Overall survival	The OS rates at 5 years were similar between the UFT/LV and surgery alone groups (66.1% vs. 66.8%, Fig 2-B) with the hazard ratio of 0.80 (95% confidence interval, 0.48–1.35; P = 0.409).
c	UFT / LV	oral UFT / LV or surgery alone	OS rates	The OS rates at 5 years were similar between the UFT/LV and surgery alone groups (66.1% vs. 66.8%, Fig 2-B) with the hazard ratio of 0.80 (95% confidence interval, 0.48–1.35; P = 0.409).
gold	Uracil-tegafur and leucovorin	Control	Resection rates	The resection rates for the first recurrence were similar between the UFT/LV and surgery alone groups
c	UFT / LV	oral UFT / LV or surgery alone	resection rates for the first recurrence	The resection rates for the first recurrence were similar between the UFT/LV and surgery alone groups (55.9% vs. 41.0%).
gold	alvimopan	pre–alvimopan	Utilization of total parenteral nutrition	Utilization of total parenteral nutrition was higher in the pre–alvimopan group (38.8% pre–alvimopan 20.6% vs. alvimopan, p = 0.010).
x	alvimopan	pre – alvimopan	Utilization of total parenteral nutrition	Utilization of total parenteral nutrition was higher in the pre–alvimopan group (38.8% pre–alvimopan 20.6% vs. alvimopan, p = 0.010).
gold	alvimopan	control	length of stay (LOS)	Patients who received alvimopan experienced a shorter length of stay (LOS) versus those in who did not receive alvimopan (10.5 vs. 8.6 days, p = 0.005, 95% CI 0.6–3.3).
c	alvimopan	Alvimopan	length of stay ( LOS )	Patients who received alvimopan experienced a shorter length of stay (LOS) versus those in who did not receive alvimopan (10.5 vs. 8.6 days, p = 0.005, 95% CI 0.6–3.3).
gold	alvimopan	control	Costs	Costs were significantly lower in the alvimopan group than the control groups (2012 USD 32,443 vs. 40,604 p <0.001).
c	alvimopan	alvimopan Alvimopan	Costs	Costs were significantly lower in the alvimopan group than the control groups (2012 USD 32,443 vs. 40,604 p <0.001).
gold	alvimopan	pre–alvimopan	disposition of patients from the OR to the intensive care unit	There was increased disposition of patients from the OR to the intensive care unit in the alvimopan group (44% vs. 66%, p = 0.048).
c	alvimopan	alvimopan Alvimopan	disposition of patients from the OR to the intensive care unit	There was increased disposition of patients from the OR to the intensive care unit in the alvimopan group (44% vs. 66%, p = 0.048).
gold	alvimopan	pre–alvimopan	use of robotic technique	Additionally, use of robotic technique increased markedly in the alvimopan group (8% vs. 25%, p = 0.030).
c	alvimopan	alvimopan Alvimopan	use of robotic technique	Additionally, use of robotic technique increased markedly in the alvimopan group (8% vs. 25%, p = 0.030).
gold	alvimopan	pre–alvimopan	Time to regular diet	Time to regular diet was significantly longer in the pre–alvimopan cohort at 7.1 days compared to 4.8 days in the treatment group (p = 0.020)
c	alvimopan	Alvimopan	Time to regular diet	Time to regular diet was significantly longer in the pre–alvimopan cohort at 7.1 days compared to 4.8 days in the treatment group (p = 0.020).
gold	Ephedrine	Control (nothing)	Heart rate	No significant change in PR was detected in normal saline group (93.9 ± 18.3 vs. 93.8 ± 17.2 beats/min; P = 0.938) or the Ephedrine group (100.1 ± 20.9 vs. 97.6 ± 12.9; P = 0.341).
x	Ephedrine	normal saline	PR	No significant change in PR was detected in normal saline group (93.9 ± 18.3 vs. 93.8 ± 17.2 beats/min; P = 0.938) or the Ephedrine group (100.1 ± 20.9 vs. 97.6 ± 12.9; P = 0.341).
gold	Digestion-resistant maltodextrin	Placebo	Colonic transit time	The total CTT, left SCTT and rectosigmoidal SCTT were significantly decreased in the RMD group after intervention compared to baseline (p < 0.004, p < 0.008 and p < 0.006, respectively), while no decrease was found in the placebo group.
c	placebo	abdominal X - ray	total CTT , left SCTT and rectosigmoidal SCTT	The total CTT, left SCTT and rectosigmoidal SCTT were significantly decreased in the RMD group after intervention compared to baseline (p < 0.004, p < 0.008 and p < 0.006, respectively), while no decrease was found in the placebo group.
gold	Ivermectin	thiabendazole	Meet all criteria for "being cured"	Based on the primary endpoint (all criteria fulfilled), the subjects cured were 60/106 (56.6%) and 48/92 (52.2%) in ivermectin and thiabendazole arm, respectively (p = 0.53).
x	ivermectin	thiabendazole	cured	Based on the primary endpoint (all criteria fulfilled), the subjects cured were 60/106 (56.6%) and 48/92 (52.2%) in ivermectin and thiabendazole arm, respectively (p = 0.53).
gold	Ivermectin	Thiabendazole	Side effects (grade 2)	Only 5/115 (4.3%) patients in the ivermectin arm presented effects of grade 2 (requiring medication), while in thiabendazole arm 43/108 patients (39.8) presented effects of grade 2 (p = 0.00).
o	ivermectin	thiabendazole	Side effects	Only 5/115 (4.3%) patients in the ivermectin arm presented effects of grade 2 (requiring medication), while in thiabendazole arm 43/108 patients (39.8) presented effects of grade 2 (p = 0.00).
gold	600,000 IU of Intramuscular vitamin D3	placebo for 2 doses	number of zones involved	Interpretation of chest radiographs at 12 weeks showed that the mean number of zones involved in the vitamin D arm were 1.35 v/s 1.82 zones in the placebo arm (p 0.004) (95% CI 0.15, 0.79).
x	placebo	vitamin D	mean number of zones involved	Interpretation of chest radiographs at 12 weeks showed that the mean number of zones involved in the vitamin D arm were 1.35 v/s 1.82 zones in the placebo arm (p 0.004) (95% CI 0.15, 0.79).
gold	600,000 IU of Intramuscular vitamin D3	placebo for 2 doses	cavity size	106 (89.8%) patients in the vitamin D arm had 50% or more reduction in cavity size v/s 111 (94.8%) in the placebo arm (p 0.035).
x	placebo	vitamin D	cavity size	106 (89.8%) patients in the vitamin D arm had 50% or more reduction in cavity size v/s 111 (94.8%) in the placebo arm (p 0.035).
gold	Chlorproguanil-dapsone (CPD)	Sulphadoxine-pyrimethamine (SP) 	Hemoglobin levels at days 7, 14, and 28	No differences in mean Hb level were observed after treatment with CPD or SP.
c	CPD	CPD	mean Hb level	No differences in mean Hb level were observed after treatment with CPD or SP.
gold	Group F receiving preoperative flupirtine	Group C receiving identical-looking placebo	number of patients and dosage of esmolol	Again to ensure induced hypotension, dose of esmolol and the number of patients treated with it were significantly higher (P < 0.05) in Group C than F [Table 1].
c	esmolol	hypotensive anesthesia	number of patients treated	Again to ensure induced hypotension, dose of esmolol and the number of patients treated with it were significantly higher (P < 0.05) in Group C than F [Table 1].
gold	Group F receiving preoperative flupirtine	Group C receiving identical-looking placebo	number of patients and dosage of esmolol	Again to ensure induced hypotension, dose of esmolol and the number of patients treated with it were significantly higher (P < 0.05) in Group C than F [Table 1].
c	esmolol	magnesium sulfate	induced hypotension , dose of	Again to ensure induced hypotension, dose of esmolol and the number of patients treated with it were significantly higher (P < 0.05) in Group C than F [Table 1].
gold	Succinylcholine group	Cisatracurium group	developed fasciculation	97.5% of the patients who had received Succinylcholine developed fasciculation, while none of the patients in the Cisatraciruim arm showed similar problem (P < 0.001).
x	Cisatraciruim	Succinylcholine	fasciculation	97.5% of the patients who had received Succinylcholine developed fasciculation, while none of the patients in the Cisatraciruim arm showed similar problem (P < 0.001).
gold	Succinylcholine group	Cisatracurium group	Muscle ache and fasciculation	Muscle ache and fasciculation was experienced in 85% of the patients in Succinylcholine group and 27.5% of the Cisatracurium group (P = 0.002).
x	Cisatracurium	Succinylcholine	Muscle ache and fasciculation	Muscle ache and fasciculation was experienced in 85% of the patients in Succinylcholine group and 27.5% of the Cisatracurium group (P = 0.002).
gold	Succinylcholine group	Cisatracurium group	sore throat 2 hours post–operation	hese numbers decreased at 2 hours post–operation (42% in the Succinylcholine group and 17.5% in the Cisatracurium group) but the difference was still statistically significant (P = 0.027).
o	Cisatracurium	Succinylcholine	post operative sore throat	These numbers decreased at 2 hours post–operation (42% in the Succinylcholine group and 17.5% in the Cisatracurium group) but the difference was still statistically significant (P = 0.027).
gold	d-xylose	sucralose	plasma GLP-1 before consuming the meal	Plasma GLP-1 concentrations were higher after d-xylose than control only before the meal (P < 0.05) but were sustained postprandially when combined with sitagliptin (P < 0.05).
x	sitagliptin	d - xylose	Plasma GLP - 1 concentrations	Plasma GLP-1 concentrations were higher after d-xylose than control only before the meal (P < 0.05) but were sustained postprandially when combined with sitagliptin (P < 0.05).
gold	propofol induction guided by BIS	propofol induction guided by clinical signs	dosage of propofol required by males	On comparing the dosage of propofol in males among the groups there was a significantly lower dosage of propofol required in group B (2.06±0.45 mg/kg and 1.83±0.32 mg/kg, respectively, P=0.016).
c	propofol	anesthesia	dosage	On comparing the dosage of propofol in males among the groups there was a significantly lower dosage of propofol required in group B (2.06±0.45 mg/kg and 1.83±0.32 mg/kg, respectively, P=0.016).
gold	propofol induction guided by BIS	propofol induction guided by clinical signs	dosage of propofol required by males	On comparing the dosage of propofol among males of the two groups, a significantly lower dosage of propofol was observed in group B (2.06±0.45 mg/kg and 1.83±0.32 mg/kg, respectively, P=0.016).
c	propofol	anesthesia	dosage	On comparing the dosage of propofol among males of the two groups, a significantly lower dosage of propofol was observed in group B (2.06±0.45 mg/kg and 1.83±0.32 mg/kg, respectively, P=0.016).
gold	propofol induction guided by BIS	propofol induction guided by clinical signs	dosage of propofol required by males	On comparing the dosage of propofol among males of the two groups, a significantly lower dosage of propofol was observed in group B (2.06±0.45 mg/kg and 1.83±0.32 mg/kg, respectively, P=0.016).
c	propofol	anesthesia	dosage of	On comparing the dosage of propofol among males of the two groups, a significantly lower dosage of propofol was observed in group B (2.06±0.45 mg/kg and 1.83±0.32 mg/kg, respectively, P=0.016).
gold	vitamin D 4000 IE/day	untreated (control)	infections after 3 months	After 3 months of vitamin D supplementation a statistically significant mean difference between the groups with regards to infections could be observed, with lower values in the vitamin D treated group; -26% (95% CI -41%–(-12%)) (Tables 2 and 3, Fig 2C).
x	vitamin D supplementation	vitamin D	infections	After 3 months of vitamin D supplementation a statistically significant mean difference between the groups with regards to infections could be observed, with lower values in the vitamin D treated group; -26% (95% CI -41%–(-12%)) (Tables 2 and 3, Fig 2C).
gold	10 mg rosuvastatin over 4 months with zinc (30 mg/d) and selenium (150 Î1⁄4g/d) supplementation.	10 mg rosuvastatin over 4 months	Triglycerides concentrations	Triglycerides concentrations dropped noticeably in both groups, though this pattern was significant only for the placebo group (P = 0.034); despite this, differences between the two groups were not significant (P = 0.76)
c	placebo	Zn / Se	Triglycerides concentrations	Triglycerides concentrations dropped noticeably in both groups, though this pattern was significant only for the placebo group (P = 0.034); despite this, differences between the two groups were not significant (P = 0.76).
gold	B. papyrifera (capsule 300 mg, twice a day)	placebo	California verbal learning test (CVLT), and symbol digit modality test (SDMT)	Although the number of patients who improved after receiving the drug in the treatment group was more than the placebo group in CVLT and SDMT, such a difference was not statistically significant (P = 0.2000 for SDMT, P = 0.1700 for CVLT); r
c	placebo	interferon therapy	number of patients who improved	Although the number of patients who improved after receiving the drug in the treatment group was more than the placebo group in CVLT and SDMT, such a difference was not statistically significant (P = 0.2000 for SDMT, P = 0.1700 for CVLT); regarding BVMT-R, our findings were statistically significant (P < 0.001).
gold	Olanzapine orodispersible tablet	Olanzapine conventional tablet	Patients with at least one adverse effect	The total number of patients with at least one AE while treated with ODT was 42 (16.8%) and with OCT 31 (12.5%) (P=0.31)
x	OCT	ODT	total number of patients with at least one AE	The total number of patients with at least one AE while treated with ODT was 42 (16.8%) and with OCT 31 (12.5%) (P=0.31) (Table III).
gold	Olanzapine orodispersible tablet	Olanzapine conventional tablet	Preference	A total of 175 patients answered a preference question: 106 (61%) preferred ODT and 48 (27%) preferred OCT (P<0.001 adjusted for treatment sequence); 21 (12%) expressed no preference.
o	OCT	ODT	Total preference	A total of 175 patients answered a preference question: 106 (61%) preferred ODT and 48 (27%) preferred OCT (P<0.001 adjusted for treatment sequence); 21 (12%) expressed no preference.
gold	chemoimmunotherapy with bevacizumab (PCR-B)	chemoimmunotherapy without bevacizumab (PCR)	progression-free survival (PFS)	Patients treated with PCR-B had a trend for a higher complete remission (CR) rate (54.5% vs 31.3%; p = 0.08), longer progression-free survival (PFS)(p = 0.06)
c	PCR - B	PCR - B	progression - free survival ( PFS )(	Patients treated with PCR-B had a trend for a higher complete remission (CR) rate (54.5% vs 31.3%; p = 0.08), longer progression-free survival (PFS)(p = 0.06) and treatment-free survival (TFS)(p = 0.09).
gold	chemoimmunotherapy with bevacizumab (PCR-B)	chemoimmunotherapy without bevacizumab (PCR)	progression-free survival (PFS)	Patients treated with PCR-B had a trend for a higher complete remission (CR) rate (54.5% vs 31.3%; p = 0.08), longer progression-free survival (PFS)(p = 0.06)
c	PCR - B	PCR - B	complete remission ( CR ) rate	Patients treated with PCR-B had a trend for a higher complete remission (CR) rate (54.5% vs 31.3%; p = 0.08), longer progression-free survival (PFS)(p = 0.06) and treatment-free survival (TFS)(p = 0.09).
gold	chemoimmunotherapy with bevacizumab (PCR-B)	chemoimmunotherapy without bevacizumab (PCR)	progression-free survival (PFS)	Patients treated with PCR-B had a trend for a higher complete remission (CR) rate (54.5% vs 31.3%; p = 0.08), longer progression-free survival (PFS)(p = 0.06)
c	PCR - B	PCR - B	treatment - free survival ( TFS )(	Patients treated with PCR-B had a trend for a higher complete remission (CR) rate (54.5% vs 31.3%; p = 0.08), longer progression-free survival (PFS)(p = 0.06) and treatment-free survival (TFS)(p = 0.09).
gold	chemoimmunotherapy with bevacizumab (PCR-B)	chemoimmunotherapy without bevacizumab (PCR)	treatment-free survival (TFS)	No differences in PFS and TFS by IGHV mutational status were observed with the addition of bevacizumab.
c	bevacizumab .	PCR in combination with bevacizumab ( PCR - B	PFS and TFS	No differences in PFS and TFS by IGHV mutational status were observed with the addition of bevacizumab.
gold	Calcitriol + Hind-limb suspension	Control 	Alkaline phosphatase	The levels of these biomarkers were lower in those who were submitted to tail suspension model and received calcitriol supplementation compared to those who were only submitted to tail suspension (60.14 ± 11.73 ng/mL vs. 58.29 ± 2.69 ng/mL; p = 0.696 for osteocalcin and 381.86 ± 99.16 mU/mL vs. 362.57 ± 27.41 ng/mL; p = 0.635 for alkaline phosphatase).
c	calcitriol supplementation	calcitriol supplementation	levels of these biomarkers	The levels of these biomarkers were lower in those who were submitted to tail suspension model and received calcitriol supplementation compared to those who were only submitted to tail suspension (60.14 ± 11.73 ng/mL vs. 58.29 ± 2.69 ng/mL; p = 0.696 for osteocalcin and 381.86 ± 99.16 mU/mL vs. 362.57 ± 27.41 ng/mL; p = 0.635 for alkaline phosphatase).
gold	Calcitriol + Hind-limb suspension	Control 	Alkaline phosphatase	and higher values regarding ALP compared to the control group (370.71 ± 84.02 mU/mL vs. 362.57 ± 27.41 mU/mL; p = 0.814)
c	calcitriol	no intervention , no tail suspension )	ALP	Those who received calcitriol and were submitted to hindlimb suspension during the study had lower values for OC and ALP at the end of the study compared to the only suspended group (53.43 ± 7.27 ng/mL vs. 60.14 ± 11.73 ng/mL; p = 0.227 for osteocalcin, 370.71 ± 84.02 mU/mL vs. 381.86 ± 99.16 mU/mL; p = 0.824 for alkaline phosphatase) and higher values regarding ALP compared to the control group (370.71 ± 84.02 mU/mL vs. 362.57 ± 27.41 mU/mL; p = 0.814) and lower values regarding OC compared to control group (53.43 ± 7.27 ng/mL vs. 58.29 ± 2.69 ng/mL; p = 0.138) though the differences were not significant.
gold	Calcitriol + Hind-limb suspension	Control 	Alkaline phosphatase	and higher values regarding ALP compared to the control group (370.71 ± 84.02 mU/mL vs. 362.57 ± 27.41 mU/mL; p = 0.814)
c	calcitriol	calcitriol	OC and ALP	Those who received calcitriol and were submitted to hindlimb suspension during the study had lower values for OC and ALP at the end of the study compared to the only suspended group (53.43 ± 7.27 ng/mL vs. 60.14 ± 11.73 ng/mL; p = 0.227 for osteocalcin, 370.71 ± 84.02 mU/mL vs. 381.86 ± 99.16 mU/mL; p = 0.824 for alkaline phosphatase) and higher values regarding ALP compared to the control group (370.71 ± 84.02 mU/mL vs. 362.57 ± 27.41 mU/mL; p = 0.814) and lower values regarding OC compared to control group (53.43 ± 7.27 ng/mL vs. 58.29 ± 2.69 ng/mL; p = 0.138) though the differences were not significant.
gold	Extracorporeal shock wave therapy	Control	Plantar fascia thickness	After treatment, the mean plantar fascia thickness was significantly decreased in the ESWT group (P < 0.001), while it was slightly increased in the placebo group (P = 0.03)
x	ESWT	placebo	mean plantar fascia thickness	After treatment, the mean plantar fascia thickness was significantly decreased in the ESWT group (P < 0.001), while it was slightly increased in the placebo group (P = 0.03), Figure 2.
gold	Extracorporeal shock wave therapy	Control	Plantar fascia thickness	Over the study period, plantar fascia thickness significantly reduced in the ESWT group (4.1 ± 1.3 to 3.6 ± 1.2 mm, P < 0.001), but slightly increased in the sham group (4.1 ± 0.8 to 4.5 ± 0.9 mm, P = 0.03).
c	ESWT	sham therapy	plantar fascia thickness	Over the study period, plantar fascia thickness significantly reduced in the ESWT group (4.1 ± 1.3 to 3.6 ± 1.2 mm, P < 0.001), but slightly increased in the sham group (4.1 ± 0.8 to 4.5 ± 0.9 mm, P = 0.03).
gold	Extracorporeal shock wave therapy	Control	Pain 	Both groups showed significant pain improvement over the course of the study (P < 0.001), though pain scores were significantly more reduced in the ESWT than the sham group (-4.2 ± 2.9 vs. -2.7 ± 1.8, P = 0.049).
c	ESWT	sham therapy	pain scores	Both groups showed significant pain improvement over the course of the study (P < 0.001), though pain scores were significantly more reduced in the ESWT than the sham group (-4.2 ± 2.9 vs. -2.7 ± 1.8, P = 0.049).
gold	Extracorporeal shock wave therapy	Control	Pain 	Both groups showed significant pain improvement over the course of the study (P < 0.001), though pain scores were significantly more reduced in the ESWT than the sham group (-4.2 ± 2.9 vs. -2.7 ± 1.8, P = 0.049).
c	ESWT	sham therapy	pain improvement	Both groups showed significant pain improvement over the course of the study (P < 0.001), though pain scores were significantly more reduced in the ESWT than the sham group (-4.2 ± 2.9 vs. -2.7 ± 1.8, P = 0.049).
gold	Extracorporeal shock wave therapy	Control	Pain 	after three months follow-up, pain scores was significantly lower in the ESWT group than in the placebo group (P = 0.04).
c	placebo	extracorporeal shock wave therapy ( ESWT )	pain scores	Table 2 Comparison of pain scores and plantar fascia thickness before and after the study within and between the two groups   Regarding the NRS pain scores, no significant difference were observed between the pain scores of the two groups at baseline (P = 0.59), but after three months follow-up, pain scores was significantly lower in the ESWT group than in the placebo group (P = 0.04).
gold	Extracorporeal shock wave therapy	Control	Pain 	after three months follow-up, pain scores was significantly lower in the ESWT group than in the placebo group (P = 0.04).
c	placebo	extracorporeal shock wave therapy ( ESWT )	NRS pain scores	Table 2 Comparison of pain scores and plantar fascia thickness before and after the study within and between the two groups   Regarding the NRS pain scores, no significant difference were observed between the pain scores of the two groups at baseline (P = 0.59), but after three months follow-up, pain scores was significantly lower in the ESWT group than in the placebo group (P = 0.04).
gold	Extracorporeal shock wave therapy	Control	Pain 	after three months follow-up, pain scores was significantly lower in the ESWT group than in the placebo group (P = 0.04).
c	placebo	ESWT	pain scores and plantar fascia thickness	Table 2 Comparison of pain scores and plantar fascia thickness before and after the study within and between the two groups   Regarding the NRS pain scores, no significant difference were observed between the pain scores of the two groups at baseline (P = 0.59), but after three months follow-up, pain scores was significantly lower in the ESWT group than in the placebo group (P = 0.04).
gold	coenzyme Q10 supplementation 	placebo	inflammatory markers	In other word, compared with the placebo group, inflammatory markers were significantly lower in the group of CoQ10.
c	placebo	CoQ10 supplement	inflammatory markers	In other word, compared with the placebo group, inflammatory markers were significantly lower in the group of CoQ10.
gold	coenzyme Q10 supplementation 	placebo	levels of serum CK	levels of serum CK in CoQ10 group was significantly increased following the short-term supplementation and running 3000 meters like-competitive (Table 2) (p=0.073).
c	CoQ10	CoQ10 supplements	levels of serum CK	In contrast, levels of serum CK in CoQ10 group was significantly increased following the short-term supplementation and running 3000 meters like-competitive (Table 2) (p=0.073).
gold	vitamin A group	placebo group	serum ferritin level	The findings showed that the reduction in serum ferritin level and the increments in haemoglobin, serum iron and transferrin saturation were found to be significant among children allocated to the vitamin A group compared to those allocated to the placebo group (p < 0.01).
x	vitamin A	placebo	reduction in serum ferritin level	The findings showed that the reduction in serum ferritin level and the increments in haemoglobin, serum iron and transferrin saturation were found to be significant among children allocated to the vitamin A group compared to those allocated to the placebo group (p < 0.01).
gold	vitamin A group	placebo group	serum ferritin level	The findings showed that the reduction in serum ferritin level and the increments in haemoglobin, serum iron and transferrin saturation were found to be significant among children allocated to the vitamin A group compared to those allocated to the placebo group (p < 0.01).
x	vitamin A	placebo	increments in haemoglobin , serum iron and transferrin saturation	The findings showed that the reduction in serum ferritin level and the increments in haemoglobin, serum iron and transferrin saturation were found to be significant among children allocated to the vitamin A group compared to those allocated to the placebo group (p < 0.01).
gold	Betamethasone valerate medicated plaster (Betesil®)	Aescin 10% cream	Improvement in ecchymosis/hematoma scores	using the ecchymosis/hematoma score, no significant difference between Betesil® and aescin 10% cream groups was observed.
x	Betesil ®	aescin	ecchymosis / hematoma score	However, using the ecchymosis/hematoma score, no significant difference between Betesil® and aescin 10% cream groups was observed.
gold	Betamethasone valerate medicated plaster (Betesil®)	Aescin 10% cream	Patients' satisfaction	Patients' satisfaction was significantly higher among subjects receiving Betesil®, if compared to patients receiving aescin 10% cream (P < 0.01).
x	Betesil ®,	aescin	Patients ' satisfaction	Patients' satisfaction was significantly higher among subjects receiving Betesil®, if compared to patients receiving aescin 10% cream (P < 0.01).
gold	Bremelanotide 1.25	Placebo	Sexual distress improvement 	For 1.25/1.75-mg pooled versus placebo, mean changes from baseline to study end were +0.7 versus +0.2 satisfying sexual events/month (p = 0.0180), +3.6 versus +1.9 female sexual function index total score (p = 0.0017), −11.1 versus −6.8 female sexual distress scale-desire/arousal/orgasm total score (p = 0.0014)
c	placebo	subcutaneous BMT	sexual function index	For 1.25/1.75-mg pooled versus placebo, mean changes from baseline to study end were +0.7 versus +0.2 satisfying sexual events/month (p = 0.0180), +3.6 versus +1.9 female sexual function index total score (p = 0.0017), −11.1 versus −6.8 female sexual distress scale-desire/arousal/orgasm total score (p = 0.0014).
gold	Bremelanotide 1.25	Placebo	Sexual distress improvement 	For 1.25/1.75-mg pooled versus placebo, mean changes from baseline to study end were +0.7 versus +0.2 satisfying sexual events/month (p = 0.0180), +3.6 versus +1.9 female sexual function index total score (p = 0.0017), −11.1 versus −6.8 female sexual distress scale-desire/arousal/orgasm total score (p = 0.0014)
c	placebo	subcutaneous BMT	sexual distress scale - desire / arousal / orgasm total score	For 1.25/1.75-mg pooled versus placebo, mean changes from baseline to study end were +0.7 versus +0.2 satisfying sexual events/month (p = 0.0180), +3.6 versus +1.9 female sexual function index total score (p = 0.0017), −11.1 versus −6.8 female sexual distress scale-desire/arousal/orgasm total score (p = 0.0014).
gold	Bremelanotide 1.75	Placebo	Satisfying sexual events/month	the mean (SD) change in number of SSEs from baseline to EOS was +0.7 (2.4) events/month for BMT 1.25/1.75 mg pooled, compared with +0.2 (2.3) for placebo (p = 0.0180).
c	placebo	subcutaneous BMT	mean ( SD ) change in number of SSEs	In the mITT population, the mean (SD) change in number of SSEs from baseline to EOS was +0.7 (2.4) events/month for BMT 1.25/1.75 mg pooled, compared with +0.2 (2.3) for placebo (p = 0.0180).
gold	CZP 200 mg every 2 weeks (Q2W) or CZP 400 mg every 4 weeks (Q4W)	Placebo	absenteeism and presenteeism	employed CZP patients reported an average of 1.0–1.8 and 3.0–3.9 fewer days of absenteeism and presenteeism, respectively, per month compared with 1.0 and 0.3 fewer days for placebo patients (p<0.05).
x	placebo	CZP	absenteeism and presenteeism	By week 24, employed CZP patients reported an average of 1.0–1.8 and 3.0–3.9 fewer days of absenteeism and presenteeism, respectively, per month compared with 1.0 and 0.3 fewer days for placebo patients (p<0.05).
gold	CZP 200 mg every 2 weeks (Q2W) or CZP 400 mg every 4 weeks (Q4W)	placebo	household work days	CZP patients reported an average of 3.0–3.5 household work days gained per month versus 1.0 day for placebo (p<0.05).
x	placebo	CZP	household work days	Within the home, by week 24, CZP patients reported an average of 3.0–3.5 household work days gained per month versus 1.0 day for placebo (p<0.05).
gold	CZP 200 mg every 2 weeks (Q2W) or CZP 400 mg every 4 weeks (Q4W)	placebo	household work days	Further improvements were reported in CZP-treated patients up to week 24 with an average of 3.0–3.5 fewer days with no household work, 3.6–4.2 fewer days with reduced household productivity, and PsA interference with productivity within the home reduced by 2.3–3.0, compared with an average of 1.0 less day with no household work per month (p<0.05; either CZP arm vs placebo),
x	placebo	CZP	PsA interference with productivity within the home	Further improvements were reported in CZP-treated patients up to week 24 with an average of 3.0–3.5 fewer days with no household work, 3.6–4.2 fewer days with reduced household productivity, and PsA interference with productivity within the home reduced by 2.3–3.0, compared with an average of 1.0 less day with no household work per month (p<0.05; either CZP arm vs placebo), 1.8 fewer days per month with reduced productivity (p<0.05; either CZP arm vs placebo), and PsA interference with work reduced by 0.8 in placebo patients (p<0.05; either CZP arm vs placebo) (figure 3).
gold	CZP 200 mg every 2 weeks (Q2W) or CZP 400 mg every 4 weeks (Q4W)	placebo	household work days	Further improvements were reported in CZP-treated patients up to week 24 with an average of 3.0–3.5 fewer days with no household work, 3.6–4.2 fewer days with reduced household productivity, and PsA interference with productivity within the home reduced by 2.3–3.0, compared with an average of 1.0 less day with no household work per month (p<0.05; either CZP arm vs placebo),
x	placebo	CZP	PsA interference with work	Further improvements were reported in CZP-treated patients up to week 24 with an average of 3.0–3.5 fewer days with no household work, 3.6–4.2 fewer days with reduced household productivity, and PsA interference with productivity within the home reduced by 2.3–3.0, compared with an average of 1.0 less day with no household work per month (p<0.05; either CZP arm vs placebo), 1.8 fewer days per month with reduced productivity (p<0.05; either CZP arm vs placebo), and PsA interference with work reduced by 0.8 in placebo patients (p<0.05; either CZP arm vs placebo) (figure 3).
gold	CZP 200 mg every 2 weeks (Q2W) or CZP 400 mg every 4 weeks (Q4W)	placebo	household work days	Further improvements were reported in CZP-treated patients up to week 24 with an average of 3.0–3.5 fewer days with no household work, 3.6–4.2 fewer days with reduced household productivity, and PsA interference with productivity within the home reduced by 2.3–3.0, compared with an average of 1.0 less day with no household work per month (p<0.05; either CZP arm vs placebo),
x	placebo	CZP	productivity	Further improvements were reported in CZP-treated patients up to week 24 with an average of 3.0–3.5 fewer days with no household work, 3.6–4.2 fewer days with reduced household productivity, and PsA interference with productivity within the home reduced by 2.3–3.0, compared with an average of 1.0 less day with no household work per month (p<0.05; either CZP arm vs placebo), 1.8 fewer days per month with reduced productivity (p<0.05; either CZP arm vs placebo), and PsA interference with work reduced by 0.8 in placebo patients (p<0.05; either CZP arm vs placebo) (figure 3).
gold	CZP 200 mg every 2 weeks (Q2W) or CZP 400 mg every 4 weeks (Q4W)	placebo	household work days	Further improvements were reported in CZP-treated patients up to week 24 with an average of 3.0–3.5 fewer days with no household work, 3.6–4.2 fewer days with reduced household productivity, and PsA interference with productivity within the home reduced by 2.3–3.0, compared with an average of 1.0 less day with no household work per month (p<0.05; either CZP arm vs placebo),
x	placebo	CZP	no household work	Further improvements were reported in CZP-treated patients up to week 24 with an average of 3.0–3.5 fewer days with no household work, 3.6–4.2 fewer days with reduced household productivity, and PsA interference with productivity within the home reduced by 2.3–3.0, compared with an average of 1.0 less day with no household work per month (p<0.05; either CZP arm vs placebo), 1.8 fewer days per month with reduced productivity (p<0.05; either CZP arm vs placebo), and PsA interference with work reduced by 0.8 in placebo patients (p<0.05; either CZP arm vs placebo) (figure 3).
gold	CZP 200 mg every 2 weeks (Q2W) or CZP 400 mg every 4 weeks (Q4W)	placebo	household work days	Further improvements were reported in CZP-treated patients up to week 24 with an average of 3.0–3.5 fewer days with no household work, 3.6–4.2 fewer days with reduced household productivity, and PsA interference with productivity within the home reduced by 2.3–3.0, compared with an average of 1.0 less day with no household work per month (p<0.05; either CZP arm vs placebo),
x	placebo	CZP	household productivity	Further improvements were reported in CZP-treated patients up to week 24 with an average of 3.0–3.5 fewer days with no household work, 3.6–4.2 fewer days with reduced household productivity, and PsA interference with productivity within the home reduced by 2.3–3.0, compared with an average of 1.0 less day with no household work per month (p<0.05; either CZP arm vs placebo), 1.8 fewer days per month with reduced productivity (p<0.05; either CZP arm vs placebo), and PsA interference with work reduced by 0.8 in placebo patients (p<0.05; either CZP arm vs placebo) (figure 3).
gold	Vaginal estriol plus viable Lactobacillus acidophilus KS400 	Placebo	Improvement in Vaginal Maturation Index	The Controlled phase results for a change in VMI demonstrated superiority of the 0.03 mg estriol–lactobacilli combination to placebo (p < 0.001)
x	estriol – lactobacilli	placebo	VMI	The Controlled phase results for a change in VMI demonstrated superiority of the 0.03 mg estriol–lactobacilli combination to placebo (p < 0.001).
gold	Vilazodone	Placebo	Overall severity category shift from ≥ 4 to ≤ 2 	A significantly greater proportion of vilazodone-treated versus placebo-treated patients shifted from baseline ≥ 4 to end of study ≤ 2 on MADRS items of apparent sadness, reported sadness, inner tension, reduced sleep, and lassitude (OR range, 1.5–2.0, P < .05).
x	vilazodone - treated	placebo	MADRS items of apparent sadness , reported sadness , inner tension , reduced sleep , and lassitude	A significantly greater proportion of vilazodone-treated versus placebo-treated patients shifted from baseline ≥ 4 to end of study ≤ 2 on MADRS items of apparent sadness, reported sadness, inner tension, reduced sleep, and lassitude (OR range, 1.5–2.0, P < .05).
gold	Vilazodone	Placebo	Abscense of anxious depression	a significantly greater proportion of vilazodone-treated versus placebo-treated patients shifted from anxious depression at baseline to no anxious depression at end of study (OR = 1.5, P = .031).
x	vilazodone - treated	placebo	no anxious depression	Additionally, a significantly greater proportion of vilazodone-treated versus placebo-treated patients shifted from anxious depression at baseline to no anxious depression at end of study (OR = 1.5, P = .031).
gold	Vilazodone	Placebo	Abscense of anxious depression	a significantly greater proportion of vilazodone-treated versus placebo-treated patients shifted from anxious depression at baseline to no anxious depression at end of study (OR = 1.5, P = .031).
x	vilazodone - treated	placebo	anxious depression	Additionally, a significantly greater proportion of vilazodone-treated versus placebo-treated patients shifted from anxious depression at baseline to no anxious depression at end of study (OR = 1.5, P = .031).
gold	Vilazodone	Placebo	Overall severity category shift from ≥ 4 to ≤ 2 	a significantly greater proportion of vilazodone-treated versus placebo-treated patients improved from baseline ≥ 4 (moderate to severe symptoms) to end of study ≤ 2 (mild to no symptoms)
x	vilazodone - treated	placebo	suicidal thoughts	On 5 of 9 evaluable MADRS single items (suicidal thoughts [item 10] was not evaluable due to low number of observations), a significantly greater proportion of vilazodone-treated versus placebo-treated patients improved from baseline ≥ 4 (moderate to severe symptoms) to end of study ≤ 2 (mild to no symptoms) (Figure 3).
gold	Bilastine updosing to 80 mg	placebo	histamine assessed 1–3 h after cold challenge 	Microdialysis levels of histamine, IL-6 and IL-8 assessed 1–3 h after cold challenge were significantly (P < 0.05) decreased following up-dosing with 80 mg bilastine.
c	bilastine	H1 - antihistamine , bilastine	Microdialysis levels of histamine , IL - 6 and IL - 8	Microdialysis levels of histamine, IL-6 and IL-8 assessed 1–3 h after cold challenge were significantly (P < 0.05) decreased following up-dosing with 80 mg bilastine.
gold	Bilastine updosing to 80 mg	placebo	IL-8 assessed 1–3 h after cold challenge 	However, up-dosing with 80 mg bilastine daily for 7 days caused a 34% (P = 0.026) reduction in IL-6 and a 37% (P = 0.004) reduction in IL-8 compared with when the patients were untreated.
c	bilastine	H1 - antihistamine	IL - 6	However, up-dosing with 80 mg bilastine daily for 7 days caused a 34% (P = 0.026) reduction in IL-6 and a 37% (P = 0.004) reduction in IL-8 compared with when the patients were untreated.
gold	Bilastine updosing to 80 mg	placebo	IL-8 assessed 1–3 h after cold challenge 	However, up-dosing with 80 mg bilastine daily for 7 days caused a 34% (P = 0.026) reduction in IL-6 and a 37% (P = 0.004) reduction in IL-8 compared with when the patients were untreated.
c	bilastine	H1 - antihistamine	IL - 8	However, up-dosing with 80 mg bilastine daily for 7 days caused a 34% (P = 0.026) reduction in IL-6 and a 37% (P = 0.004) reduction in IL-8 compared with when the patients were untreated.
gold	Lax-Asab powder	placebo	mean of weekly defecation frequency increase	The mean of weekly defecation frequency increased in both groups; from 1.8 ± 0.41 to 4.8 ± 1.12 times in patients who received Lax-Asab and from 1.7 ± 0.44 to 2.2 ± 0.61 times in patients who received placebo.
x	placebo	Lax - Asab	mean of weekly defecation frequency	The mean of weekly defecation frequency increased in both groups; from 1.8 ± 0.41 to 4.8 ± 1.12 times in patients who received Lax-Asab and from 1.7 ± 0.44 to 2.2 ± 0.61 times in patients who received placebo.
gold	Lax-Asab powder	placebo	Improvement in other measured outcomes concerning defecation difficulty	All the other measured outcomes concerning defecation difficulty were significantly improved in patients receiving Lax-Asab compared with placebo.
x	placebo .	Lax - Asab	defecation difficulty	All the other measured outcomes concerning defecation difficulty were significantly improved in patients receiving Lax-Asab compared with placebo.
gold	Lax-Asab powder	placebo	tolerability of treating patients with chronic functional constipation	Side effects were reported by three patients who received placebo and by seven who received Lax-Asab [odds ratio = 3.05; 95% confidence interval (0.65–14.13); p = 0.27].
x	placebo	Lax - Asab	Side effects	Side effects were reported by three patients who received placebo and by seven who received Lax-Asab [odds ratio = 3.05; 95% confidence interval (0.65–14.13); p = 0.27].
gold	Lax-Asab powder	placebo	efficacy of treating patients with chronic functional constipation	This study confirms the efficacy and tolerability of an Iranian herbal preparation, Lax-Asab, in treating patients with chronic functional constipation.
c	Iranian herbal preparation , Lax - Asab	Lax - Asab	efficacy and tolerability	This study confirms the efficacy and tolerability of an Iranian herbal preparation, Lax-Asab, in treating patients with chronic functional constipation.
gold	Extended-release oxcarbazepine 2400 mg	Control	Seizure median percent improvement in North America	both SPN-804 dosages were significantly superior to placebo in median percent seizure reduction (placebo: −13.3%; 1200 mg: −34.5%, P = 0.02; 2400 mg: −52.7%, P = 0.006) in the North American study site cluster
x	SPN - 804	placebo	percent seizure reduction	When data were analyzed separately for study site clusters, a post hoc analysis demonstrated that both SPN-804 dosages were significantly superior to placebo in median percent seizure reduction (placebo: −13.3%; 1200 mg: −34.5%, P = 0.02; 2400 mg: −52.7%, P = 0.006) in the North American study site cluster.
gold	Transcranial direct current stimulation (tDCS)	baseline	acute medication intake	Preventive treatment with anodal tDCS turned out to be beneficial in MoA: migraine attack frequency, migraine days, attack duration and acute medication intake significantly decreased during the treatment period compared to pre-treatment baseline (all p < 0.05), and this benefit persisted on average 4.8 weeks after the end of tDCS.
c	tDCS	tDCS	migraine attack frequency , migraine days , attack duration and acute medication intake	Preventive treatment with anodal tDCS turned out to be beneficial in MoA: migraine attack frequency, migraine days, attack duration and acute medication intake significantly decreased during the treatment period compared to pre-treatment baseline (all p < 0.05), and this benefit persisted on average 4.8 weeks after the end of tDCS.
gold	Ketamine + Risperidone	Placebo	Smooth pursuit eye movements velocity gain	In addition, the ketamine-treated groups showed worse performance on both SPEM velocity gain and saccadic frequency compared with placebo.
x	ketamine	placebo	SPEM velocity gain and saccadic frequency	In addition, the ketamine-treated groups showed worse performance on both SPEM velocity gain and saccadic frequency compared with placebo.
gold	Ketamine 	Placebo	Smooth pursuit saccadic frequency	Ketamine increased saccadic frequency and decreased velocity gain of SPEM (all P<0.01) but had no significant effects on PS or AS (all P⩾0.07).
c	Ketamine	Ketamine	velocity gain of SPEM	Ketamine increased saccadic frequency and decreased velocity gain of SPEM (all P<0.01) but had no significant effects on PS or AS (all P⩾0.07).
gold	Ketamine 	Placebo	Smooth pursuit saccadic frequency	Ketamine increased saccadic frequency and decreased velocity gain of SPEM (all P<0.01) but had no significant effects on PS or AS (all P⩾0.07).
c	Ketamine	Ketamine	PS or AS	Ketamine increased saccadic frequency and decreased velocity gain of SPEM (all P<0.01) but had no significant effects on PS or AS (all P⩾0.07).
gold	Ketamine 	Placebo	Smooth pursuit saccadic frequency	Ketamine increased saccadic frequency and decreased velocity gain of SPEM (all P<0.01) but had no significant effects on PS or AS (all P⩾0.07).
c	Ketamine	ketamine solution	saccadic frequency	Ketamine increased saccadic frequency and decreased velocity gain of SPEM (all P<0.01) but had no significant effects on PS or AS (all P⩾0.07).
gold	oxycodone (OXY) 60mg oral	placebo (PBO)	median Emax scores	median Emax scores were significantly higher with both doses of oxycodone compared with placebo (P < 0.0001 for both pairwise comparisons)
x	oxycodone	placebo	median Emax scores	scores of 85.8 ± 14.3 for oxycodone 30 mg, and 90.9 ± 11.5 for oxycodone 60 mg, which were 30–35 points higher than placebo, and median Emax scores were significantly higher with both doses of oxycodone compared with placebo (P < 0.0001 for both pairwise comparisons), demonstrating study validity (Table 2).
gold	oxycodone (OXY) 30mg oral	eluxadoline 100, 300, and 1000 mg	mean Emax scores	Mean Emax scores were between 25 and 35 points lower with eluxadoline compared with oxycodone, with median Emax scores being significantly higher for both doses of oxycodone compared with all eluxadoline doses (P < 0.0001 for all pairwise comparisons).
x	eluxadoline	oxycodone	median Emax scores	Mean Emax scores were between 25 and 35 points lower with eluxadoline compared with oxycodone, with median Emax scores being significantly higher for both doses of oxycodone compared with all eluxadoline doses (P < 0.0001 for all pairwise comparisons).
gold	oxycodone (OXY) 30mg oral	eluxadoline 100, 300, and 1000 mg	mean Emax scores	Mean Emax scores were between 25 and 35 points lower with eluxadoline compared with oxycodone, with median Emax scores being significantly higher for both doses of oxycodone compared with all eluxadoline doses (P < 0.0001 for all pairwise comparisons).
x	eluxadoline	oxycodone	Mean Emax scores	Mean Emax scores were between 25 and 35 points lower with eluxadoline compared with oxycodone, with median Emax scores being significantly higher for both doses of oxycodone compared with all eluxadoline doses (P < 0.0001 for all pairwise comparisons).
gold	oxycodone (OXY) intranasal	eluxadoline	median Emax scores	median Emax scores were significantly greater for both doses of oxycodone compared with both eluxadoline doses (P < 0.0001 for all pairwise comparisons).
x	eluxadoline	oxycodone	median Emax scores	Mean Emax scores were again 30–35 points higher for oxycodone than for eluxadoline, and median Emax scores were significantly greater for both doses of oxycodone compared with both eluxadoline doses (P < 0.0001 for all pairwise comparisons).
gold	oxycodone (OXY) intranasal	eluxadoline	median Emax scores	median Emax scores were significantly greater for both doses of oxycodone compared with both eluxadoline doses (P < 0.0001 for all pairwise comparisons).
x	eluxadoline	oxycodone	Mean Emax scores	Mean Emax scores were again 30–35 points higher for oxycodone than for eluxadoline, and median Emax scores were significantly greater for both doses of oxycodone compared with both eluxadoline doses (P < 0.0001 for all pairwise comparisons).
gold	abatacept	tocilizumab	treatment of RA (Rheumatoid arthritis) patients with a high disease activity at baseline	In patients with a high disease activity at baseline, the clinical efficacy of abatacept was similar to adalimumab and tocilizumab.
x	abatacept	tocilizumab .	clinical efficacy	In patients with a high disease activity at baseline, the clinical efficacy of abatacept was similar to adalimumab and tocilizumab.
gold	abatacept	tocilizumab	treatment of RA (Rheumatoid arthritis) patients with a high disease activity at baseline	In patients with a high disease activity at baseline, the clinical efficacy of abatacept was similar to adalimumab and tocilizumab.
x	abatacept	tocilizumab .	disease activity	In patients with a high disease activity at baseline, the clinical efficacy of abatacept was similar to adalimumab and tocilizumab.
gold	abatacept	tocilizumab	treatment of RA (Rheumatoid arthritis) patients with a high disease activity at baseline	In patients with a high disease activity at baseline, the clinical efficacy of abatacept was similar to adalimumab and tocilizumab.
x	abatacept	adalimumab	clinical efficacy	In patients with a high disease activity at baseline, the clinical efficacy of abatacept was similar to adalimumab and tocilizumab.
gold	abatacept	tocilizumab	treatment of RA (Rheumatoid arthritis) patients with a high disease activity at baseline	In patients with a high disease activity at baseline, the clinical efficacy of abatacept was similar to adalimumab and tocilizumab.
x	abatacept	adalimumab	disease activity	In patients with a high disease activity at baseline, the clinical efficacy of abatacept was similar to adalimumab and tocilizumab.
gold	abatacept	tocilizumab	treatment of RA (Rheumatoid arthritis) patients with a high disease activity at baseline	In patients with a high disease activity at baseline, the clinical efficacy of abatacept was similar to adalimumab and tocilizumab.
x	tocilizumab .	adalimumab	clinical efficacy	In patients with a high disease activity at baseline, the clinical efficacy of abatacept was similar to adalimumab and tocilizumab.
gold	abatacept	tocilizumab	treatment of RA (Rheumatoid arthritis) patients with a high disease activity at baseline	In patients with a high disease activity at baseline, the clinical efficacy of abatacept was similar to adalimumab and tocilizumab.
x	tocilizumab .	adalimumab	disease activity	In patients with a high disease activity at baseline, the clinical efficacy of abatacept was similar to adalimumab and tocilizumab.
gold	Laparoscopic hysterectomy	Abdominal hysterectom	Hospital stay	he duration of the postoperative hospital stay for the patients who underwent laparoscopic hysterectomy was 5.6 ± 0.5 days as compared to 7.9 ± 0.2 days for the patients who underwent abdominal hysterectomy (P < 0.05).
x	laparoscopic hysterectomy	abdominal hysterectomy	duration of the postoperative hospital stay	The duration of the postoperative hospital stay for the patients who underwent laparoscopic hysterectomy was 5.6 ± 0.5 days as compared to 7.9 ± 0.2 days for the patients who underwent abdominal hysterectomy (P < 0.05).
gold	Laparoscopic hysterectomy	Abdominal hysterectom	C-reactive protein 	The mean CRP concentration at 24 hr postoperatively was 10.8 mg/L in the patients who underwent laparoscopic hysterectomy as compared to that of the patients who underwent abdominal hysterectomy (39.5 mg/L) (P < 0.05)
x	laparoscopic hysterectomy	abdominal hysterectomy	mean CRP concentration	The mean CRP concentration at 24 hr postoperatively was 10.8 mg/L in the patients who underwent laparoscopic hysterectomy as compared to that of the patients who underwent abdominal hysterectomy (39.5 mg/L) (P < 0.05) and there was correlation with between the cytokine and CRP levels (Pearson correlation coefficient r = 0.796; P < 0.05).
gold	Laparoscopic hysterectomy	Abdominal hysterectom	C-reactive protein 	The mean CRP concentration at 24 hr postoperatively was 10.8 mg/L in the patients who underwent laparoscopic hysterectomy as compared to that of the patients who underwent abdominal hysterectomy (39.5 mg/L) (P < 0.05)
x	laparoscopic hysterectomy	abdominal hysterectomy	cytokine and CRP levels	The mean CRP concentration at 24 hr postoperatively was 10.8 mg/L in the patients who underwent laparoscopic hysterectomy as compared to that of the patients who underwent abdominal hysterectomy (39.5 mg/L) (P < 0.05) and there was correlation with between the cytokine and CRP levels (Pearson correlation coefficient r = 0.796; P < 0.05).
gold	Laparoscopic hysterectomy	Abdominal hysterectom	IL-6 levels 	The peak serum IL-6 (P < 0.05) and CRP concentrations were significantly less increased in the laparoscopic group as compared with that of the abdominal hysterectomy group (P < 0.05)
c	abdominal hysterectomy	abdominal hysterectomy	CRP concentrations	The peak serum IL-6 (P < 0.05) and CRP concentrations were significantly less increased in the laparoscopic group as compared with that of the abdominal hysterectomy group (P < 0.05), while the serum cortisol concentration showed a similar time course and changes and there were no significant difference between the groups.
gold	Laparoscopic hysterectomy	Abdominal hysterectom	IL-6 levels 	The peak serum IL-6 (P < 0.05) and CRP concentrations were significantly less increased in the laparoscopic group as compared with that of the abdominal hysterectomy group (P < 0.05)
c	abdominal hysterectomy	abdominal hysterectomy	peak serum IL - 6	The peak serum IL-6 (P < 0.05) and CRP concentrations were significantly less increased in the laparoscopic group as compared with that of the abdominal hysterectomy group (P < 0.05), while the serum cortisol concentration showed a similar time course and changes and there were no significant difference between the groups.
gold	Laparoscopic hysterectomy	Abdominal hysterectom	IL-6 levels 	The peak serum IL-6 (P < 0.05) and CRP concentrations were significantly less increased in the laparoscopic group as compared with that of the abdominal hysterectomy group (P < 0.05)
i	laparoscopic hysterectomy	abdominal hysterectomy	serum cortisol concentration	The peak serum IL-6 (P < 0.05) and CRP concentrations were significantly less increased in the laparoscopic group as compared with that of the abdominal hysterectomy group (P < 0.05), while the serum cortisol concentration showed a similar time course and changes and there were no significant difference between the groups.
gold	Combining nateglinide + vildagliptin	Switching from nateglinide to vildagliptin	Postprandial glucose	The addition of vildagliptin to nateglinide significantly reduced glucose levels at 15, 30, 60, 120 and 180 min compared with switching from nateglinide to vildagliptin (8.4 and 10.0 at 15 min, P < 0.01; 9.0 and 11.5 at 30 min, P < 0.001; 9.8 and 13.4 at 60 min
x	nateglinide to vildagliptin	vildagliptin to nateglinide	glucose levels	The addition of vildagliptin to nateglinide significantly reduced glucose levels at 15, 30, 60, 120 and 180 min compared with switching from nateglinide to vildagliptin (8.4 and 10.0 at 15 min, P < 0.01; 9.0 and 11.5 at 30 min, P < 0.001; 9.8 and 13.4 at 60 min, P < 0.001; 8.4 and 11.2 at 120 min, P < 0.001; 6.4 and 8.4 mmol/L at 180 min, P < 0.01, respectively; Figure 3a).
gold	single real session biparietal tDCS	single sham session combined with neglect therapy	alertness	After the single sham session combined with neglect therapy alertness worsened significantly (intrinsic: T = 39, p < 0.001; phasic: T = 38, p < 0.001), whereas after the single real session, alertness improved significantly (intrinsic: T = 45, p = 0.008; phasic: T = 49, p < 0.001)
c	neglect therapy	neglect therapy	alertness	After the single sham session combined with neglect therapy alertness worsened significantly (intrinsic: T = 39, p < 0.001; phasic: T = 38, p < 0.001), whereas after the single real session, alertness improved significantly (intrinsic: T = 45, p = 0.008; phasic: T = 49, p < 0.001).
gold	Mobile phone intervention	Standard care	Tetanus vaccination	In the intervention group 72% of nullipara women received two doses of tetanus vaccination versus 56% in the control group (OR, 1.62; 95% CI, 0.81-3.26)
o	preventive malaria treatment	tetanus vaccination	number of women receiving anti - tetanus vaccinations , preventive treatment for malaria , gestational age at last antenatal care visit , antepartum referrals and the timing of the mentioned services in gestational age	In the intervention group 72% of nullipara women received two doses of tetanus vaccination versus 56% in the control group (OR, 1.62; 95% CI, 0.81-3.26) and 65% received two doses of preventive malaria treatment versus 52% in the control group (OR, 1.97; 95% CI, 0.98-3.94).
gold	Tofacitinib 10 mg	Placebo	Inflammatory Bowel Disease Questionnaire improvement (Induction 1)	In both OCTAVE Induction 1 and 2, treatment with tofacitinib 10 mg BID resulted in statistically significant improvements from baseline in mean IBDQ total score versus placebo at Week 4 and Week 8 [p < 0.0001 for all comparisons;
x	tofacitinib	placebo	mean IBDQ total score	In both OCTAVE Induction 1 and 2, treatment with tofacitinib 10 mg BID resulted in statistically significant improvements from baseline in mean IBDQ total score versus placebo at Week 4 and Week 8 [p < 0.0001 for all comparisons; Figure 1A and B].
gold	Tofacitinib 5 mg	Placebo	IBDQ least squares mean changes from baseline 	Statistically significant [p < 0.01 for all comparisons at Week 4 and Week 8] improvements in mean changes from baseline in all four IBDQ domain scores were seen with tofacitinib 10 mg BID versus placebo
x	tofacitinib	placebo	IBDQ domain scores	Statistically significant [p < 0.01 for all comparisons at Week 4 and Week 8] improvements in mean changes from baseline in all four IBDQ domain scores were seen with tofacitinib 10 mg BID versus placebo in both OCTAVE Induction 1 and 2 [Table 2].
gold	Tofacitinib 10 mg	Placebo	IBDQ least squares mean changes from baseline 	LS mean changes from baseline in IBDQ total score were maintained [with respect to baseline of OCTAVE Sustain] with tofacitinib 5 mg BID and tofacitinib 10 mg BID compared with placebo at all time points [p < 0.0001 for all comparisons
x	tofacitinib	placebo	IBDQ total score	LS mean changes from baseline in IBDQ total score were maintained [with respect to baseline of OCTAVE Sustain] with tofacitinib 5 mg BID and tofacitinib 10 mg BID compared with placebo at all time points [p < 0.0001 for all comparisons; Figure 1C].
gold	Tofacitinib 10 mg	Placebo	Remission 	This IBDQ remission was maintained by significantly greater proportions of patients receiving either dose of tofacitinib versus placebo throughout OCTAVE Sustain [p < 0.0001 for all comparisons].2
x	tofacitinib	placebo	IBDQ response	This IBDQ remission was maintained by significantly greater proportions of patients receiving either dose of tofacitinib versus placebo throughout OCTAVE Sustain [p < 0.0001 for all comparisons].25 At baseline of OCTAVE Sustain, 81.3% [n/N = 161/198] of patients in the placebo group, 82.3% [163/198] of patients in the tofacitinib 5 mg BID group, and 84.3% [166/197] of patients in the tofacitinib 10 mg BID group had IBDQ response [with respect to induction study baseline].
gold	Tofacitinib 10 mg	Placebo	Remission 	This IBDQ remission was maintained by significantly greater proportions of patients receiving either dose of tofacitinib versus placebo throughout OCTAVE Sustain [p < 0.0001 for all comparisons].2
x	tofacitinib	placebo	IBDQ remission	This IBDQ remission was maintained by significantly greater proportions of patients receiving either dose of tofacitinib versus placebo throughout OCTAVE Sustain [p < 0.0001 for all comparisons].25 At baseline of OCTAVE Sustain, 81.3% [n/N = 161/198] of patients in the placebo group, 82.3% [163/198] of patients in the tofacitinib 5 mg BID group, and 84.3% [166/197] of patients in the tofacitinib 10 mg BID group had IBDQ response [with respect to induction study baseline].
gold	DNA prime-rAd5 boost vaccine	Control	HIV-specific antibody response	We found that the DNA prime-rAd5 boost vaccine induced a significant cross-clade HIV-specific antibody response, which correlated with antibody neutralization efficiency.
c	DNA prime - rAd5 boost vaccine	DNA prime - rAd5 boost	cross - clade HIV - specific antibody response	We found that the DNA prime-rAd5 boost vaccine induced a significant cross-clade HIV-specific antibody response, which correlated with antibody neutralization efficiency.
gold	Risedronate 5 mg	Placebo	Hip fracture frequency	After 3 years, hip fracture had occurred in 3.8% of risedronate-treated patients and 7.4% of placebo-treated patients (relative risk 0.54; 95% confidence interval 0.32–0.91; P = 0.019).
x	placebo	risedronate	hip fracture	After 3 years, hip fracture had occurred in 3.8% of risedronate-treated patients and 7.4% of placebo-treated patients (relative risk 0.54; 95% confidence interval 0.32–0.91; P = 0.019).
gold	Risedronate 5 mg	Placebo	Hip fracture frequency	Compared with placebo, risedronate 2.5 mg or 5.0 mg once daily reduced the risk of hip fracture by 46% (relative risk [RR] 0.54; 95% CI 0.32–0.91; P = 0.019)
x	risedronate	placebo	risk of hip fracture	Compared with placebo, risedronate 2.5 mg or 5.0 mg once daily reduced the risk of hip fracture by 46% (relative risk [RR] 0.54; 95% CI 0.32–0.91; P = 0.019) in women aged 70–100 years with established osteoporosis (Table 3).3 This was a numerical larger risk reduction than that found in the overall ITT population from the HIP study (RR 0.7; 95% CI 0.6–0.9; P = 0.02) (Table 3).
gold	SRIs (clomipramine and paroxetine)	placebo	oxytocin levels	During treatment, plasma oxytocin did not differ between SRI and placebo treatment.
c	placebo	selective serotonin reuptake inhibitors ( SSRI	plasma oxytocin	During treatment, plasma oxytocin did not differ between SRI and placebo treatment.
gold	cohort A, hCG application was performed two days before blastocyst transfer, 	cohort B, the administration of hCG occurred just prior to embryo transfer on day 5	pregnancy rates (PR), clinical pregnancy rates (cPR), miscarriage rates (MR), and live birth rates (LBR)	No statistically significant differences in PR (31.7 % vs. 29.5 %, respectively), cPR (19.5 % vs. 20.5 %, respectively), LBR (17.1 % vs. 18.2 %, respectively), and MR (2.4 % vs. 2.3 %, respectively) were found after intrauterine hCG vs. medium injection.
c	hCG	uterine injection of embryo culture medium	cPR	No statistically significant differences in PR (31.7 % vs. 29.5 %, respectively), cPR (19.5 % vs. 20.5 %, respectively), LBR (17.1 % vs. 18.2 %, respectively), and MR (2.4 % vs. 2.3 %, respectively) were found after intrauterine hCG vs. medium injection.
gold	cohort A, hCG application was performed two days before blastocyst transfer, 	cohort B, the administration of hCG occurred just prior to embryo transfer on day 5	pregnancy rates (PR), clinical pregnancy rates (cPR), miscarriage rates (MR), and live birth rates (LBR)	No statistically significant differences in PR (31.7 % vs. 29.5 %, respectively), cPR (19.5 % vs. 20.5 %, respectively), LBR (17.1 % vs. 18.2 %, respectively), and MR (2.4 % vs. 2.3 %, respectively) were found after intrauterine hCG vs. medium injection.
c	hCG	uterine injection of embryo culture medium	LBR	No statistically significant differences in PR (31.7 % vs. 29.5 %, respectively), cPR (19.5 % vs. 20.5 %, respectively), LBR (17.1 % vs. 18.2 %, respectively), and MR (2.4 % vs. 2.3 %, respectively) were found after intrauterine hCG vs. medium injection.
gold	cohort A, hCG application was performed two days before blastocyst transfer, 	cohort B, the administration of hCG occurred just prior to embryo transfer on day 5	pregnancy rates (PR), clinical pregnancy rates (cPR), miscarriage rates (MR), and live birth rates (LBR)	No statistically significant differences in PR (31.7 % vs. 29.5 %, respectively), cPR (19.5 % vs. 20.5 %, respectively), LBR (17.1 % vs. 18.2 %, respectively), and MR (2.4 % vs. 2.3 %, respectively) were found after intrauterine hCG vs. medium injection.
c	hCG	uterine injection of embryo culture medium	MR	No statistically significant differences in PR (31.7 % vs. 29.5 %, respectively), cPR (19.5 % vs. 20.5 %, respectively), LBR (17.1 % vs. 18.2 %, respectively), and MR (2.4 % vs. 2.3 %, respectively) were found after intrauterine hCG vs. medium injection.
gold	cohort A, hCG application was performed two days before blastocyst transfer, 	cohort B, the administration of hCG occurred just prior to embryo transfer on day 5	pregnancy rates (PR), clinical pregnancy rates (cPR), miscarriage rates (MR), and live birth rates (LBR)	No statistically significant differences in PR (31.7 % vs. 29.5 %, respectively), cPR (19.5 % vs. 20.5 %, respectively), LBR (17.1 % vs. 18.2 %, respectively), and MR (2.4 % vs. 2.3 %, respectively) were found after intrauterine hCG vs. medium injection.
c	hCG	uterine injection of embryo culture medium	PR	No statistically significant differences in PR (31.7 % vs. 29.5 %, respectively), cPR (19.5 % vs. 20.5 %, respectively), LBR (17.1 % vs. 18.2 %, respectively), and MR (2.4 % vs. 2.3 %, respectively) were found after intrauterine hCG vs. medium injection.
gold	cohort A, hCG application was performed two days before blastocyst transfer, 	cohort B, the administration of hCG occurred just prior to embryo transfer on day 5	pregnancy rates (PR), clinical pregnancy rates (cPR), miscarriage rates (MR), and live birth rates (LBR)	No statistically significant differences were observed in PR (43.1 % vs. 48.7 %, respectively), LBR (28.7 % vs. 35.0 %, respectively), and MR (4.4 % vs. 5.9 %, respectively) after injection with hCG vs. medium.
c	hCG	injection with medium	LBR	No statistically significant differences were observed in PR (43.1 % vs. 48.7 %, respectively), LBR (28.7 % vs. 35.0 %, respectively), and MR (4.4 % vs. 5.9 %, respectively) after injection with hCG vs. medium.
gold	cohort A, hCG application was performed two days before blastocyst transfer, 	cohort B, the administration of hCG occurred just prior to embryo transfer on day 5	pregnancy rates (PR), clinical pregnancy rates (cPR), miscarriage rates (MR), and live birth rates (LBR)	No statistically significant differences were observed in PR (43.1 % vs. 48.7 %, respectively), LBR (28.7 % vs. 35.0 %, respectively), and MR (4.4 % vs. 5.9 %, respectively) after injection with hCG vs. medium.
c	hCG	injection with medium	MR	No statistically significant differences were observed in PR (43.1 % vs. 48.7 %, respectively), LBR (28.7 % vs. 35.0 %, respectively), and MR (4.4 % vs. 5.9 %, respectively) after injection with hCG vs. medium.
gold	cohort A, hCG application was performed two days before blastocyst transfer, 	cohort B, the administration of hCG occurred just prior to embryo transfer on day 5	pregnancy rates (PR), clinical pregnancy rates (cPR), miscarriage rates (MR), and live birth rates (LBR)	No statistically significant differences were observed in PR (43.1 % vs. 48.7 %, respectively), LBR (28.7 % vs. 35.0 %, respectively), and MR (4.4 % vs. 5.9 %, respectively) after injection with hCG vs. medium.
c	hCG	injection with medium	PR	No statistically significant differences were observed in PR (43.1 % vs. 48.7 %, respectively), LBR (28.7 % vs. 35.0 %, respectively), and MR (4.4 % vs. 5.9 %, respectively) after injection with hCG vs. medium.
gold	Tenofovir/emtricitabine (TDF/FTC)	Abacavir/lamivudine (ABC/3TC) 	Hip bone mass density at weeks 24 and 48	In TDF/FTC-treated patients we observed significant reductions from baseline in hip and lumbar spine BMD at week 24 (−1.8% and −2.5%) and week 48 (−2.1% and −2.1%), whereas BMD was stable in patients in the ABC/3TC arm.
c	TDF / FTC	TDF	hip and lumbar spine BMD	In TDF/FTC-treated patients we observed significant reductions from baseline in hip and lumbar spine BMD at week 24 (−1.8% and −2.5%) and week 48 (−2.1% and −2.1%), whereas BMD was stable in patients in the ABC/3TC arm.
gold	Tenofovir/emtricitabine (TDF/FTC)	Abacavir/lamivudine (ABC/3TC) 	Hip bone mass density at weeks 24 and 48	In TDF/FTC-treated patients we observed significant reductions from baseline in hip and lumbar spine BMD at week 24 (−1.8% and −2.5%) and week 48 (−2.1% and −2.1%), whereas BMD was stable in patients in the ABC/3TC arm.
c	TDF / FTC	TDF	BMD	In TDF/FTC-treated patients we observed significant reductions from baseline in hip and lumbar spine BMD at week 24 (−1.8% and −2.5%) and week 48 (−2.1% and −2.1%), whereas BMD was stable in patients in the ABC/3TC arm.
gold	Tenofovir/emtricitabine (TDF/FTC)	Abacavir/lamivudine (ABC/3TC) 	Bone turnover biomarkers (except osteoprotegerin)	All bone turnover biomarkers except osteoprotegerin increased in the TDF/FTC arm compared with the ABC/3TC arm
c	TDF / FTC	TDF	BMD .	All bone turnover biomarkers except osteoprotegerin increased in the TDF/FTC arm compared with the ABC/3TC arm, but early changes did not predict subsequent loss of BMD.
gold	Tenofovir/emtricitabine (TDF/FTC)	Abacavir/lamivudine (ABC/3TC) 	Bone turnover biomarkers (except osteoprotegerin)	All bone turnover biomarkers except osteoprotegerin increased in the TDF/FTC arm compared with the ABC/3TC arm
c	TDF / FTC	TDF	bone turnover biomarkers except osteoprotegerin	All bone turnover biomarkers except osteoprotegerin increased in the TDF/FTC arm compared with the ABC/3TC arm, but early changes did not predict subsequent loss of BMD.
gold	Tenofovir/emtricitabine (TDF/FTC)	Abacavir/lamivudine (ABC/3TC) 	Hip bone mass density at weeks 24 and 48	We observed significant reductions from baseline in both hip and lumbar spine BMD at week 24 and 48 among TDF/FTC-treated patients, whereas BMD was stable in patients in the ABC/3TC arm.
c	TDF / FTC	TDF / FTC or ABC / 3TC - based treatment	hip and lumbar spine BMD	We observed significant reductions from baseline in both hip and lumbar spine BMD at week 24 and 48 among TDF/FTC-treated patients, whereas BMD was stable in patients in the ABC/3TC arm.
gold	Tenofovir/emtricitabine (TDF/FTC)	Abacavir/lamivudine (ABC/3TC) 	Hip bone mass density at weeks 24 and 48	We observed significant reductions from baseline in both hip and lumbar spine BMD at week 24 and 48 among TDF/FTC-treated patients, whereas BMD was stable in patients in the ABC/3TC arm.
c	TDF / FTC	TDF / FTC or ABC / 3TC - based treatment	BMD	We observed significant reductions from baseline in both hip and lumbar spine BMD at week 24 and 48 among TDF/FTC-treated patients, whereas BMD was stable in patients in the ABC/3TC arm.
gold	Prolonged-release melatonin	Placebo	Adverse events 	Drug-related AEs were reported by eight patients (20.5%) in the PRM and by two (5.9%) in the placebo cohort, with no statistical difference between the two groups (post hoc analysis) (chi-squared Fisher's exact test, P=0.0933).
c	placebo	PRM therapy	Drug - related AEs	Drug-related AEs were reported by eight patients (20.5%) in the PRM and by two (5.9%) in the placebo cohort, with no statistical difference between the two groups (post hoc analysis) (chi-squared Fisher's exact test, P=0.0933).
gold	memory game with fruit	no fruit game	overall fruit intake	The main finding is that playing a memory-game containing fruit increases overall fruit intake (P = 0.016).
c	memory - game containing fruit	memory - game with fruit	overall fruit intake	The main finding is that playing a memory-game containing fruit increases overall fruit intake (P = 0.016).
gold	memory game with fruit	no fruit game	higher grape intake	Children who played the fruit version of the memory-game ate more bananas (P = 0.015) and mandarins (P = 0.036) than children who played the non-food memory-game; no effects were found for apples (P > 0.05) and grapes (P > 0.05)
c	non - food memory - game	non - food memory - game	bananas	Children who played the fruit version of the memory-game ate more bananas (P = 0.015) and mandarins (P = 0.036) than children who played the non-food memory-game; no effects were found for apples (P > 0.05) and grapes (P > 0.05).
gold	memory game with fruit	no fruit game	higher grape intake	Children who played the fruit version of the memory-game ate more bananas (P = 0.015) and mandarins (P = 0.036) than children who played the non-food memory-game; no effects were found for apples (P > 0.05) and grapes (P > 0.05)
c	non - food memory - game	food - cue exposure ( energy - densed snacks or fruit )	mandarins	Children who played the fruit version of the memory-game ate more bananas (P = 0.015) and mandarins (P = 0.036) than children who played the non-food memory-game; no effects were found for apples (P > 0.05) and grapes (P > 0.05).
gold	Palonosetron	Ondansetron	Incidence of vomiting 	However, the incidence of vomiting was lower in the palonosetron group than in the ondansetron group (18% vs. 4%, P = 0.025).
x	palonosetron	ondansetron	incidence of vomiting	However, the incidence of vomiting was lower in the palonosetron group than in the ondansetron group (18% vs. 4%, P = 0.025).
gold	(B) the Mechanical insufflation-exsufflation (MI-E) extubation protocol (study group)	(A) a conventional extubation protocol (control group)	the reintubation rates related to noninvasive ventilation (NIV) failure	the reintubation rates related to NIV failure were significantly lower in the study group when compared with controls
c	NIV	NIV	reintubation rates	Considering only the subgroup of patients that used NIV, the reintubation rates related to NIV failure were significantly lower in the study group when compared with controls; two patients (6%) versus 13 (33%); P < 0.05, respectively.
gold	(B) the Mechanical insufflation-exsufflation (MI-E) extubation protocol (study group)	(A) a conventional extubation protocol (control group)	the reintubation rates related to noninvasive ventilation (NIV) failure	the reintubation rates related to NIV failure were significantly lower in the study group when compared with controls
c	NIV	conventional extubation protocol ( control	NIV failure	Considering only the subgroup of patients that used NIV, the reintubation rates related to NIV failure were significantly lower in the study group when compared with controls; two patients (6%) versus 13 (33%); P < 0.05, respectively.
gold	delayed-release DMF 240 mg TID	placebo	mean number of new or enlarging T2-hyperintense lesions - patients newly diagnosed with relapsing–remitting multiple sclerosis (RRMS)	In a subset of patients (MRI cohort), delayed-release DMF BID and TID reduced the mean number of new or enlarging T2-hyperintense lesions by 80% and 81%, gadolinium-enhancing lesion activity by 92% and 92%, and mean number of new non-enhancing T1-hypointense lesions by 68% and 70% (all p < 0.0001 versus placebo).
x	placebo	DMF BID	mean number of new non - enhancing T1 - hypointense lesions	In a subset of patients (MRI cohort), delayed-release DMF BID and TID reduced the mean number of new or enlarging T2-hyperintense lesions by 80% and 81%, gadolinium-enhancing lesion activity by 92% and 92%, and mean number of new non-enhancing T1-hypointense lesions by 68% and 70% (all p < 0.0001 versus placebo).
gold	delayed-release DMF 240 mg TID	placebo	mean number of new or enlarging T2-hyperintense lesions - patients newly diagnosed with relapsing–remitting multiple sclerosis (RRMS)	In a subset of patients (MRI cohort), delayed-release DMF BID and TID reduced the mean number of new or enlarging T2-hyperintense lesions by 80% and 81%, gadolinium-enhancing lesion activity by 92% and 92%, and mean number of new non-enhancing T1-hypointense lesions by 68% and 70% (all p < 0.0001 versus placebo).
x	placebo	DMF BID	gadolinium - enhancing lesion activity	In a subset of patients (MRI cohort), delayed-release DMF BID and TID reduced the mean number of new or enlarging T2-hyperintense lesions by 80% and 81%, gadolinium-enhancing lesion activity by 92% and 92%, and mean number of new non-enhancing T1-hypointense lesions by 68% and 70% (all p < 0.0001 versus placebo).
gold	delayed-release DMF 240 mg TID	placebo	mean number of new or enlarging T2-hyperintense lesions - patients newly diagnosed with relapsing–remitting multiple sclerosis (RRMS)	In a subset of patients (MRI cohort), delayed-release DMF BID and TID reduced the mean number of new or enlarging T2-hyperintense lesions by 80% and 81%, gadolinium-enhancing lesion activity by 92% and 92%, and mean number of new non-enhancing T1-hypointense lesions by 68% and 70% (all p < 0.0001 versus placebo).
x	placebo	DMF BID	mean number of new or enlarging T2 - hyperintense lesions	In a subset of patients (MRI cohort), delayed-release DMF BID and TID reduced the mean number of new or enlarging T2-hyperintense lesions by 80% and 81%, gadolinium-enhancing lesion activity by 92% and 92%, and mean number of new non-enhancing T1-hypointense lesions by 68% and 70% (all p < 0.0001 versus placebo).
gold	delayed-release DMF 240 mg BID	placebo	annualized relapse rate - patients newly diagnosed with relapsing–remitting multiple sclerosis (RRMS)	At 2 years, delayed-release DMF BID and TID reduced the annualized relapse rate by 56% and 60% (both p < 0.0001)
c	placebo	delayed - release dimethyl fumarate	annualized relapse rate	At 2 years, delayed-release DMF BID and TID reduced the annualized relapse rate by 56% and 60% (both p < 0.0001), risk of relapse by 54% and 57% (both p < 0.0001), and risk of 12-week confirmed disability progression by 71% (p < 0.0001) and 47% (p = 0.0085) versus placebo.
gold	delayed-release DMF 240 mg BID	placebo	annualized relapse rate - patients newly diagnosed with relapsing–remitting multiple sclerosis (RRMS)	At 2 years, delayed-release DMF BID and TID reduced the annualized relapse rate by 56% and 60% (both p < 0.0001)
c	placebo	delayed - release dimethyl fumarate	risk of 12 - week confirmed disability progression	At 2 years, delayed-release DMF BID and TID reduced the annualized relapse rate by 56% and 60% (both p < 0.0001), risk of relapse by 54% and 57% (both p < 0.0001), and risk of 12-week confirmed disability progression by 71% (p < 0.0001) and 47% (p = 0.0085) versus placebo.
gold	delayed-release DMF 240 mg BID	placebo	annualized relapse rate - patients newly diagnosed with relapsing–remitting multiple sclerosis (RRMS)	At 2 years, delayed-release DMF BID and TID reduced the annualized relapse rate by 56% and 60% (both p < 0.0001)
c	placebo	delayed - release dimethyl fumarate	risk of relapse	At 2 years, delayed-release DMF BID and TID reduced the annualized relapse rate by 56% and 60% (both p < 0.0001), risk of relapse by 54% and 57% (both p < 0.0001), and risk of 12-week confirmed disability progression by 71% (p < 0.0001) and 47% (p = 0.0085) versus placebo.
gold	STAAR® implantable contact lens (ICL)	baseline	uncorrected visual acuity (UCVA)	There was a statistically significant difference between preoperative and postoperative UCVA in the ICL group (P = 0.000).
x	implantable contact lens and Artiflex	Artiflex	postoperative best corrected visual acuity	Table 1 The preoperative uncorrected visual acuity (Log MAR) of implantable contact lens and Artiflex group   Table 2 The preoperative best corrected visual acuity (Log MAR) of implantable contact lens and Artiflex group   Table 3 The postoperative uncorrected visual acuity of implantable contact lens and Artiflex group   Table 4 The postoperative best corrected visual acuity of implantable contact lens and Artiflex group   There was a statistically significant difference between preoperative and postoperative UCVA in the ICL group (P = 0.000).
gold	STAAR® implantable contact lens (ICL)	baseline	uncorrected visual acuity (UCVA)	There was a statistically significant difference between preoperative and postoperative UCVA in the ICL group (P = 0.000).
x	implantable contact lens and Artiflex	Artiflex	postoperative uncorrected visual acuity	Table 1 The preoperative uncorrected visual acuity (Log MAR) of implantable contact lens and Artiflex group   Table 2 The preoperative best corrected visual acuity (Log MAR) of implantable contact lens and Artiflex group   Table 3 The postoperative uncorrected visual acuity of implantable contact lens and Artiflex group   Table 4 The postoperative best corrected visual acuity of implantable contact lens and Artiflex group   There was a statistically significant difference between preoperative and postoperative UCVA in the ICL group (P = 0.000).
gold	STAAR® implantable contact lens (ICL)	baseline	uncorrected visual acuity (UCVA)	There was a statistically significant difference between preoperative and postoperative UCVA in the ICL group (P = 0.000).
x	implantable contact lens and Artiflex	Artiflex	postoperative UCVA	Table 1 The preoperative uncorrected visual acuity (Log MAR) of implantable contact lens and Artiflex group   Table 2 The preoperative best corrected visual acuity (Log MAR) of implantable contact lens and Artiflex group   Table 3 The postoperative uncorrected visual acuity of implantable contact lens and Artiflex group   Table 4 The postoperative best corrected visual acuity of implantable contact lens and Artiflex group   There was a statistically significant difference between preoperative and postoperative UCVA in the ICL group (P = 0.000).
gold	STAAR® implantable contact lens (ICL)	baseline	uncorrected visual acuity (UCVA)	There was a statistically significant difference between preoperative and postoperative UCVA in the ICL group (P = 0.000).
x	implantable contact lens and Artiflex	Artiflex	preoperative uncorrected visual acuity ( Log MAR )	Table 1 The preoperative uncorrected visual acuity (Log MAR) of implantable contact lens and Artiflex group   Table 2 The preoperative best corrected visual acuity (Log MAR) of implantable contact lens and Artiflex group   Table 3 The postoperative uncorrected visual acuity of implantable contact lens and Artiflex group   Table 4 The postoperative best corrected visual acuity of implantable contact lens and Artiflex group   There was a statistically significant difference between preoperative and postoperative UCVA in the ICL group (P = 0.000).
gold	STAAR® implantable contact lens (ICL)	baseline	uncorrected visual acuity (UCVA)	There was a statistically significant difference between preoperative and postoperative UCVA in the ICL group (P = 0.000).
x	implantable contact lens and Artiflex	Artiflex	preoperative best corrected visual acuity ( Log MAR )	Table 1 The preoperative uncorrected visual acuity (Log MAR) of implantable contact lens and Artiflex group   Table 2 The preoperative best corrected visual acuity (Log MAR) of implantable contact lens and Artiflex group   Table 3 The postoperative uncorrected visual acuity of implantable contact lens and Artiflex group   Table 4 The postoperative best corrected visual acuity of implantable contact lens and Artiflex group   There was a statistically significant difference between preoperative and postoperative UCVA in the ICL group (P = 0.000).
gold	Artiflex	baseline	uncorrected visual acuity (UCVA)	There was a statistically significant difference between preoperative and postoperative UCVA in Artiflex group (P = 0.000).
c	Artiflex	Artiflex	postoperative UCVA	There was a statistically significant difference between preoperative and postoperative UCVA in Artiflex group (P = 0.000).
gold	STAAR® implantable contact lens (ICL)	Artiflex	UCVA or BCVA	There was no statistically significant difference between postoperative UCVA or BCVA between Artiflex and ICL groups (P = 0.786).
c	Artiflex	ICL .	postoperative UCVA or BCVA	There was no statistically significant difference between postoperative UCVA or BCVA between Artiflex and ICL groups (P = 0.786).
gold	lomustine	baseline	circulating endothelial cells (CECs) after 4 and 6 weeks	In contrast, in patients receiving bevacizumab single agent and in patients receiving lomustine single agent, CECs at baseline were similar to CECs after 4 weeks and 6 weeks of treatment.
x	lomustine	bevacizumab	CECs	In contrast, in patients receiving bevacizumab single agent and in patients receiving lomustine single agent, CECs at baseline were similar to CECs after 4 weeks and 6 weeks of treatment.
gold	bevacizumab plus lomustine	baseline	circulating endothelial cells (CECs) after 4 and 6 weeks	In patients receiving bevacizumab plus lomustine combination therapy, patients had higher CECs after 4 weeks (P<0.001) and 6 weeks (P<0.001) of treatment compared with the baseline value.
c	bevacizumab plus lomustine combination	Bevacizumab	CECs	In patients receiving bevacizumab plus lomustine combination therapy, patients had higher CECs after 4 weeks (P<0.001) and 6 weeks (P<0.001) of treatment compared with the baseline value.
gold	combined NPWT with open bone graft	only open bone graft	the number of microvessels	The results showed that the number of microvessels in NPWT group was higher than that in gauze group during the whole process.
x	gauze	NPWT	number of microvessels	The results showed that the number of microvessels in NPWT group was higher than that in gauze group during the whole process.
gold	Naproxen sodium + diphenhydramine (440 mg/50 mg)	Naproxen sodium	Wake time after sleep onset improvement 	In the first study, only the NS 440 mg/DPH 50 mg combination showed significant improvements in both WASO vs. NS alone (−70.3 min p = 0.0002) and SL vs. DPH alone (25.50 and 41.50 min respectively, p < 0.0001).
o	NS	DPH	WASO and SL	In the first study, only the NS 440 mg/DPH 50 mg combination showed significant improvements in both WASO vs. NS alone (−70.3 min p = 0.0002) and SL vs. DPH alone (25.50 and 41.50 min respectively, p < 0.0001).
gold	Naproxen sodium + diphenhydramine (440mg/25mg)	Naproxen sodium	Wake time after sleep onset improvement 	the NS 440 mg/DPH 25 mg combination failed to show any significant improvements vs. either component alone.
o	NS	DPH	Global Assessment of Investigational Product as a Pain Reliever Scale	In the second study, the NS 440 mg/DPH 25 mg combination failed to show any significant improvements vs. either component alone.
gold	Ethylene di-amine tetra-acetic acid + Ethanol	Ethanol	Bond strength	The surface treatment methods did not have any significant effect (P > 0.05) on any group but EDTA group had the highest bond strength.
c	EDTA	modified wet - ethanol bonding method	bond strength .	The surface treatment methods did not have any significant effect (P > 0.05) on any group but EDTA group had the highest bond strength.
gold	Exogenous glucagon-like peptide-1 infusion	Control	Absolute insulin concentrations	The insulin/glucose ratio at 270 minutes was increased with GLP-1 infusion (GLP-1 (9.1 ± 2.7) vs. placebo (5.8 ± 1.8); P = 0.02) but there was no difference in absolute insulin concentrations.
x	placebo	GLP - 1	insulin / glucose ratio	The insulin/glucose ratio at 270 minutes was increased with GLP-1 infusion (GLP-1 (9.1 ± 2.7) vs. placebo (5.8 ± 1.8); P = 0.02) but there was no difference in absolute insulin concentrations.
gold	Exogenous glucagon-like peptide-1 infusion	Control	Absolute insulin concentrations	The insulin/glucose ratio at 270 minutes was increased with GLP-1 infusion (GLP-1 (9.1 ± 2.7) vs. placebo (5.8 ± 1.8); P = 0.02) but there was no difference in absolute insulin concentrations.
x	placebo	GLP - 1	absolute insulin concentrations .	The insulin/glucose ratio at 270 minutes was increased with GLP-1 infusion (GLP-1 (9.1 ± 2.7) vs. placebo (5.8 ± 1.8); P = 0.02) but there was no difference in absolute insulin concentrations.
gold	Exogenous glucagon-like peptide-1 infusion	Control	Glucagon concentrations during infusion	There was a transient, non-sustained, reduction in plasma glucagon concentrations during GLP-1 infusion (t = 30 minutes GLP-1 (90 ± 12 pmol/ml) vs. placebo (104 ± 10 pmol/ml); P < 0.01).
x	placebo	GLP - 1	plasma glucagon concentrations	There was a transient, non-sustained, reduction in plasma glucagon concentrations during GLP-1 infusion (t = 30 minutes GLP-1 (90 ± 12 pmol/ml) vs. placebo (104 ± 10 pmol/ml); P < 0.01).
gold	Vitamin K + supplementation	Supplementation alone	Mineral density	L3 bone mineral density has increased statistically significantly in the vitamin K group compared to the control group (0.01 ± 0.03 g/cm2 vs -0.008 ± 0.04 g/cm2, P = 0.049).
c	vitamin K	Vitamin K	L3 bone mineral density	In a per protocol analysis after 6 months, L3 bone mineral density has increased statistically significantly in the vitamin K group compared to the control group (0.01 ± 0.03 g/cm2 vs -0.008 ± 0.04 g/cm2, P = 0.049).
gold	Vitamin K + supplementation	Supplementation alone	Undercarboxylated osteocalcin	UcOC concentration was also significantly decreased in the vitamin K group (-1.6 ± 1.6 ng/dL vs -0.4 ± 1.1 ng/dL, P = 0.008).
c	vitamin K	vitamin K , anti - lipid medications , hormone replacement therapy	UcOC concentration	UcOC concentration was also significantly decreased in the vitamin K group (-1.6 ± 1.6 ng/dL vs -0.4 ± 1.1 ng/dL, P = 0.008).
gold	Vitamin K + supplementation	Supplementation alone	Mineral density	After 6 months of treatment, the L3 BMD in the vitamin K group compared to the control group increased statistically significantly (0.01 ± 0.03 g/cm2 vs -0.008 ± 0.04 g/cm2, P = 0.049)
c	vitamin K	Vitamin K	L3 BMD	After 6 months of treatment, the L3 BMD in the vitamin K group compared to the control group increased statistically significantly (0.01 ± 0.03 g/cm2 vs -0.008 ± 0.04 g/cm2, P = 0.049).
gold	Vitamin K + supplementation	Supplementation alone	Osteocalcin 	Osteocalcin level was higher in the vitamin K group than in the control group, but the difference was not significant (P = 0.14).
c	vitamin K	Vitamin K	Osteocalcin level	Osteocalcin level was higher in the vitamin K group than in the control group, but the difference was not significant (P = 0.14).
gold	mental clinical nursing pathway care	usual nursing care	Karnofsky Performance Status (KPS) of patients - (individuals diagnosed with a malignant tumor)	The KPS of patients receiving mental clinical nursing pathway care was higher than those receiving usual nursing care, and there was a statistical significant difference between the two groups (P<0.01)
x	mental clinical nursing pathway care	usual nursing care	KPS	The KPS of patients receiving mental clinical nursing pathway care was higher than those receiving usual nursing care, and there was a statistical significant difference between the two groups (P<0.01).
gold	Probiotics 	Placebo	Montgomery–Åsberg Depression Rating Scale 	At end-point, 9 (23%) of those in the probiotic group showed a ⩾60% change on the Montgomery–Åsberg Depression Rating Scale (responders), compared to 10 (26%) of those in the placebo group (χ12=0.107, p = ns).
c	placebo	probiotic formula	Montgomery – A ̊ sberg Depression Rating Scale	At end-point, 9 (23%) of those in the probiotic group showed a ⩾60% change on the Montgomery–Åsberg Depression Rating Scale (responders), compared to 10 (26%) of those in the placebo group (χ12=0.107, p = ns).
gold	glargine 300 U/ml (Gla-300)	glargine 100 U/ml (Gla-100)	annualized rate (events per participant-year) of confirmed [≤3.9 mmol/l (≤70 mg/dl)] or severe hypoglycaemia at any time of day (24 h) over the 6-month	Annualized rates of confirmed (≤3.9 mmol/l) or severe hypoglycaemia were lower with Gla-300 than with Gla-100 during the night (31% difference in rate ratio over 6 months) and at any time (24 h, 14% difference).
x	Gla - 300	Gla - 100	) or severe hypoglycaemia	Annualized rates of confirmed (≤3.9 mmol/l) or severe hypoglycaemia were lower with Gla-300 than with Gla-100 during the night (31% difference in rate ratio over 6 months) and at any time (24 h, 14% difference).
gold	glargine 300 U/ml (Gla-300)	glargine 100 U/ml (Gla-100)	annualized rate (events per participant-year) of confirmed [≤3.9 mmol/l (≤70 mg/dl)] or severe hypoglycaemia at any time of day (24 h) over the 6-month	Annualized rates of confirmed (≤3.9 mmol/l) or severe hypoglycaemia were lower with Gla-300 than with Gla-100 during the night (31% difference in rate ratio over 6 months) and at any time (24 h, 14% difference).
x	Gla - 300	Gla - 100	Annualized rates of confirmed	Annualized rates of confirmed (≤3.9 mmol/l) or severe hypoglycaemia were lower with Gla-300 than with Gla-100 during the night (31% difference in rate ratio over 6 months) and at any time (24 h, 14% difference).
gold	Outpatient Foley catheter	Inpatient vaginal PGE2	Pain 	OPC group felt less pain (significant discomfort 26% Vs 58%, p = .003), and had more sleep (5.8 Vs 3.4 hours, p < .001), during cervical preparation, but were more likely to require oxytocin IOL (88 Vs 59%, p = .001).
c	OPC	OPC	sleep	OPC group felt less pain (significant discomfort 26% Vs 58%, p = .003), and had more sleep (5.8 Vs 3.4 hours, p < .001), during cervical preparation, but were more likely to require oxytocin IOL (88 Vs 59%, p = .001).
gold	Outpatient Foley catheter	Inpatient vaginal PGE2	Pain 	OPC group felt less pain (significant discomfort 26% Vs 58%, p = .003), and had more sleep (5.8 Vs 3.4 hours, p < .001), during cervical preparation, but were more likely to require oxytocin IOL (88 Vs 59%, p = .001).
c	OPC	OPC	pain	OPC group felt less pain (significant discomfort 26% Vs 58%, p = .003), and had more sleep (5.8 Vs 3.4 hours, p < .001), during cervical preparation, but were more likely to require oxytocin IOL (88 Vs 59%, p = .001).
gold	Outpatient Foley catheter	Inpatient vaginal PGE2	Pain 	OPC group felt less pain (significant discomfort 26% Vs 58%, p = .003), and had more sleep (5.8 Vs 3.4 hours, p < .001), during cervical preparation, but were more likely to require oxytocin IOL (88 Vs 59%, p = .001).
c	OPC	OPC	oxytocin IOL	OPC group felt less pain (significant discomfort 26% Vs 58%, p = .003), and had more sleep (5.8 Vs 3.4 hours, p < .001), during cervical preparation, but were more likely to require oxytocin IOL (88 Vs 59%, p = .001).
gold	Outpatient Foley catheter	Inpatient vaginal PGE2	Hospital stay 	The OPC group spent significantly less time in hospital prior to birth, approximately 11 hours, however had a longer Birthing Unit stay, and their overall reduced inpatient stay (96 vs. 105 hours) was not statistically significant.
c	OPC	OPC	reduced inpatient stay	The OPC group spent significantly less time in hospital prior to birth, approximately 11 hours, however had a longer Birthing Unit stay, and their overall reduced inpatient stay (96 vs. 105 hours) was not statistically significant.
gold	Outpatient Foley catheter	Inpatient vaginal PGE2	Hospital stay 	The OPC group spent significantly less time in hospital prior to birth, approximately 11 hours, however had a longer Birthing Unit stay, and their overall reduced inpatient stay (96 vs. 105 hours) was not statistically significant.
c	OPC	OPC	time in hospital prior to birth	The OPC group spent significantly less time in hospital prior to birth, approximately 11 hours, however had a longer Birthing Unit stay, and their overall reduced inpatient stay (96 vs. 105 hours) was not statistically significant.
gold	Outpatient Foley catheter	Inpatient vaginal PGE2	Hospital stay 	The OPC group spent significantly less time in hospital prior to birth, approximately 11 hours, however had a longer Birthing Unit stay, and their overall reduced inpatient stay (96 vs. 105 hours) was not statistically significant.
c	OPC	OPC	Birthing Unit stay	The OPC group spent significantly less time in hospital prior to birth, approximately 11 hours, however had a longer Birthing Unit stay, and their overall reduced inpatient stay (96 vs. 105 hours) was not statistically significant.
gold	Repetitive transcranial magnetic stimulation	Sham stimulation	Proprioceptive drift effect during asynchronous stroking	Based on our assumption that rTMS stimulation would produce an effect compared to sham stimulation during synchronous stroking but not asynchronous stroking, we compared proprioceptive drift in the post-stimulation session using post hoc paired t-tests, which revealed a significantly (p < 0.025) stronger effect of rTMS versus sham stimulation on proprioceptive drift during synchronous stroking [t(15) = 2.578, p = 0.021], but not during asynchronous stroking [t(15) = 0.161, p = 0.876].
x	rTMS	sham stimulation	proprioceptive drift	Based on our assumption that rTMS stimulation would produce an effect compared to sham stimulation during synchronous stroking but not asynchronous stroking, we compared proprioceptive drift in the post-stimulation session using post hoc paired t-tests, which revealed a significantly (p < 0.025) stronger effect of rTMS versus sham stimulation on proprioceptive drift during synchronous stroking [t(15) = 2.578, p = 0.021], but not during asynchronous stroking [t(15) = 0.161, p = 0.876].
gold	Repetitive transcranial magnetic stimulation	Sham stimulation	Proprioceptive drift effect during asynchronous stroking	Based on our assumption that rTMS stimulation would produce an effect compared to sham stimulation during synchronous stroking but not asynchronous stroking, we compared proprioceptive drift in the post-stimulation session using post hoc paired t-tests, which revealed a significantly (p < 0.025) stronger effect of rTMS versus sham stimulation on proprioceptive drift during synchronous stroking [t(15) = 2.578, p = 0.021], but not during asynchronous stroking [t(15) = 0.161, p = 0.876].
x	rTMS	rTMS stimulation	proprioceptive drift	Based on our assumption that rTMS stimulation would produce an effect compared to sham stimulation during synchronous stroking but not asynchronous stroking, we compared proprioceptive drift in the post-stimulation session using post hoc paired t-tests, which revealed a significantly (p < 0.025) stronger effect of rTMS versus sham stimulation on proprioceptive drift during synchronous stroking [t(15) = 2.578, p = 0.021], but not during asynchronous stroking [t(15) = 0.161, p = 0.876].
gold	Repetitive transcranial magnetic stimulation	Sham stimulation	Proprioceptive drift effect during asynchronous stroking	Based on our assumption that rTMS stimulation would produce an effect compared to sham stimulation during synchronous stroking but not asynchronous stroking, we compared proprioceptive drift in the post-stimulation session using post hoc paired t-tests, which revealed a significantly (p < 0.025) stronger effect of rTMS versus sham stimulation on proprioceptive drift during synchronous stroking [t(15) = 2.578, p = 0.021], but not during asynchronous stroking [t(15) = 0.161, p = 0.876].
x	sham stimulation	rTMS stimulation	proprioceptive drift	Based on our assumption that rTMS stimulation would produce an effect compared to sham stimulation during synchronous stroking but not asynchronous stroking, we compared proprioceptive drift in the post-stimulation session using post hoc paired t-tests, which revealed a significantly (p < 0.025) stronger effect of rTMS versus sham stimulation on proprioceptive drift during synchronous stroking [t(15) = 2.578, p = 0.021], but not during asynchronous stroking [t(15) = 0.161, p = 0.876].
gold	flavonoid-rich blueberry drink	matched placebo	positive affect (PA)	there was a significant increase in PA after consuming the WBB drink (pre: M = 22.76, SD = 9.01 and post: M = 29.48, SD = 8.60; t(20) = −4.68, p < 0.001)
c	WBB	WBB drink for vitamin C	PA	Subsequent Bonferroni-corrected post-hoc t-tests demonstrated that there was a significant increase in PA after consuming the WBB drink (pre: M = 22.76, SD = 9.01 and post: M = 29.48, SD = 8.60; t(20) = −4.68, p < 0.001).
gold	flavonoid-rich blueberry drink	matched placebo	reduction in negative affect (NA) 2 h after consuming	NA did not change 2 h after consuming either the placebo (pre: M = 19.25, SD = 8.73 and post: M = 19.79, SD = 9.78) or the WBB drink (pre: M = 20.79, SD = 8.09 and post: M = 20.07, SD = 9.06)
c	placebo	placebo or WBB	NA	NA did not change 2 h after consuming either the placebo (pre: M = 19.25, SD = 8.73 and post: M = 19.79, SD = 9.78) or the WBB drink (pre: M = 20.79, SD = 8.09 and post: M = 20.07, SD = 9.06).
gold	Amifostine 	Control	Glomerular filtration rate fall	The median fall of the glomerular filtration rate (GFR) was 10% from baseline in the amifostine group (105 to 95 ml min−1) and 37% in the control patient group (107 to 67 ml min−1) (P< 0.01).
c	amifostine	amifostine	median fall of the glomerular filtration rate ( GFR )	The median fall of the glomerular filtration rate (GFR) was 10% from baseline in the amifostine group (105 to 95 ml min−1) and 37% in the control patient group (107 to 67 ml min−1) (P< 0.01).
gold	Amifostine 	Control	Grade III/IV stomatitis 	Stomatitis grade III/IV occurred in 25% without versus 0% of patients with amifostine (P = 0.01)
c	amifostine	amifostine	Stomatitis grade III / IV	Stomatitis grade III/IV occurred in 25% without versus 0% of patients with amifostine (P = 0.01).
gold	Amifostine 	Control	Days with fever	In addition, a lower number of days with fever and a shortened duration of hospital stay were observed in the amifostine arm.
c	amifostine	amifostine	shortened duration of hospital stay	In addition, a lower number of days with fever and a shortened duration of hospital stay were observed in the amifostine arm.
gold	Amifostine 	Control	Days with fever	In addition, a lower number of days with fever and a shortened duration of hospital stay were observed in the amifostine arm.
c	amifostine	amifostine	number of days with fever	In addition, a lower number of days with fever and a shortened duration of hospital stay were observed in the amifostine arm.
gold	Biperiden	Placebo	N1 amplitude 	Biperiden increased N1 amplitude compared to placebo (* p<0.05).
x	Biperiden	placebo	N1 amplitude	Biperiden increased N1 amplitude compared to placebo (* p<0.05).
gold	Biperiden	Placebo	Learned irrelevance index	Biperiden had no effect on the behavioural LIrr measures,
c	Biperiden	biperiden	reaction times	Biperiden had no effect on the behavioural LIrr measures, although prolonged reaction times were evident.
gold	Biperiden	Placebo	Learned irrelevance index	Biperiden had no effect on the behavioural LIrr measures,
c	Biperiden	biperiden	behavioural LIrr measures	Biperiden had no effect on the behavioural LIrr measures, although prolonged reaction times were evident.
gold	Propofol 	Thiopental	Septal mitral annular velocity during systole after 5 minutes	Among TDI two parameters demonstrated a significant inter-group difference: the S' in propofol was lower than that in Thiopental-group at T3 (p = 0.002),
x	Propofol	propofol	a ' velocities	Among TDI two parameters demonstrated a significant inter-group difference: the S' in propofol was lower than that in Thiopental-group at T3 (p = 0.002), and a' velocities were persistently lower in Propofol-group, compared with same time values in Thiopental-group (T1, T2, and T3: p = 0.025, 0.007, and 0.009, respectively).
gold	Propofol 	Thiopental	Septal mitral annular velocity during systole after 5 minutes	Among TDI two parameters demonstrated a significant inter-group difference: the S' in propofol was lower than that in Thiopental-group at T3 (p = 0.002),
x	Propofol	propofol	S '	Among TDI two parameters demonstrated a significant inter-group difference: the S' in propofol was lower than that in Thiopental-group at T3 (p = 0.002), and a' velocities were persistently lower in Propofol-group, compared with same time values in Thiopental-group (T1, T2, and T3: p = 0.025, 0.007, and 0.009, respectively).
gold	Propofol 	Thiopental	Systolic blood pressure recovery	A related pattern was observed in systolic BP: the baseline and initial decline were similar between the two groups (p = 0.193 and 0.214); however, after that thiopental group tended to recover and significantly higher level of systolic BP compared with those of propofol [T2: 121.0 (111.3-136.8) vs. 106.5 (95.3-115.0) mmHg, p = 0.014;
x	thiopental	propofol	level of systolic BP	A related pattern was observed in systolic BP: the baseline and initial decline were similar between the two groups (p = 0.193 and 0.214); however, after that thiopental group tended to recover and significantly higher level of systolic BP compared with those of propofol [T2: 121.0 (111.3-136.8) vs. 106.5 (95.3-115.0) mmHg, p = 0.014; T3: 117.0 (106.0-136.8) vs. 99.0 (91.0-110.0) mmHg, p = 0.016] (Fig.
gold	Propofol 	Thiopental	Systolic blood pressure recovery	A related pattern was observed in systolic BP: the baseline and initial decline were similar between the two groups (p = 0.193 and 0.214); however, after that thiopental group tended to recover and significantly higher level of systolic BP compared with those of propofol [T2: 121.0 (111.3-136.8) vs. 106.5 (95.3-115.0) mmHg, p = 0.014;
x	thiopental	propofol	systolic BP	A related pattern was observed in systolic BP: the baseline and initial decline were similar between the two groups (p = 0.193 and 0.214); however, after that thiopental group tended to recover and significantly higher level of systolic BP compared with those of propofol [T2: 121.0 (111.3-136.8) vs. 106.5 (95.3-115.0) mmHg, p = 0.014; T3: 117.0 (106.0-136.8) vs. 99.0 (91.0-110.0) mmHg, p = 0.016] (Fig.
gold	Litesse® Ultra polydextrose 	Placebo	Body fat mass	For relative change in body fat mass, LU + B420 showed a − 4.5% (− 1.4 kg, P = 0.02, N = 37) difference to the Placebo group, whereas LU (+ 0.3%, P = 1.00, N = 35) and B420 (− 3.0%, P = 0.28, N = 24) alone had no effect (overall ANOVA P = 0.095, Placebo N = 35).
x	LU + B420	Placebo	body fat mass	For relative change in body fat mass, LU + B420 showed a − 4.5% (− 1.4 kg, P = 0.02, N = 37) difference to the Placebo group, whereas LU (+ 0.3%, P = 1.00, N = 35) and B420 (− 3.0%, P = 0.28, N = 24) alone had no effect (overall ANOVA P = 0.095, Placebo N = 35).
gold	Litesse® Ultra polydextrose  ́+ Bifidobacterium animalisssp. lactis 420	Placebo	Energy intake	B420 and LU + B420 also significantly reduced energy intake compared to Placebo
c	Placebo	LU	energy intake	B420 and LU + B420 also significantly reduced energy intake compared to Placebo.
gold	Aloe vera aqueous extract 40 mg/kg 	Control	Equilibrium 	On the other hands, equilibrium in the group which received 10 mg/kg of Aloe vera aqueous extract daily significantly decreased (P = 0.01) (Table 2) compared with the other groups; however, this parameter in the group which received 40 mg/kg Aloe vera aqueous extract significantly increased compared with the control group (P = 0.01) (Table 2).
c	Aloe vera aqueous extract	Aloe vera aqueous extract	equilibrium	On the other hands, equilibrium in the group which received 10 mg/kg of Aloe vera aqueous extract daily significantly decreased (P = 0.01) (Table 2) compared with the other groups; however, this parameter in the group which received 40 mg/kg Aloe vera aqueous extract significantly increased compared with the control group (P = 0.01) (Table 2).
gold	Aloe vera aqueous extract 40 mg/kg 	Control	Floppy eyelids	floppy eyelids in the group which received 10 mg/kg of Aloe vera aqueous extract was significantly lower (Table 3) than that of the control group, but this parameter in the group which received 40 mg/kg Aloe vera aqueous extract was significantly higher than that of the control group (P = 0.03)
c	Aloe vera aqueous extract	Aloe vera aqueous extract	floppy eyelids	In addition, the results of the present study showed that the floppy eyelids in the group which received 10 mg/kg of Aloe vera aqueous extract was significantly lower (Table 3) than that of the control group, but this parameter in the group which received 40 mg/kg Aloe vera aqueous extract was significantly higher than that of the control group (P = 0.03) (Table 3).
gold	Aloe vera aqueous extract 40 mg/kg 	Control	Agitation	Agitation in the group which received 10 mg/kg Aloe vera aqueous extract significantly decreased (P = 0.01) (Table 4) compared with the control group, but this parameter in the group which received 40 mg/kg Aloe vera aqueous extract significantly increased compared with the control group
c	Aloe vera aqueous extract	Aloe vera	Agitation	Agitation in the group which received 10 mg/kg Aloe vera aqueous extract significantly decreased (P = 0.01) (Table 4) compared with the control group, but this parameter in the group which received 40 mg/kg Aloe vera aqueous extract significantly increased compared with the control group (Table 3).
gold	Enalapril	Olmesartan	Hyperkalemia higher than 5 mmol/L	The percentage of patients presenting hyperkalemia higher than 5 mmol/L did not differ between treatments: 37% for olmesartan and 40% for enalapril.
x	olmesartan	enalapril .	percentage of patients presenting hyperkalemia	The percentage of patients presenting hyperkalemia higher than 5 mmol/L did not differ between treatments: 37% for olmesartan and 40% for enalapril.
gold	Enalapril	Olmesartan	Glomerular filtration rate increase 	The mean e-GFR ranged 46.3 to 48.59 ml/mint/1.73 m2 in those treated with olmesartan and 46.8 to 48.3 ml/mint/1.73 m2 in those with enalapril and remained unchanged at the end of the study.
x	enalapril	olmesartan	mean e - GFR	The mean e-GFR ranged 46.3 to 48.59 ml/mint/1.73 m2 in those treated with olmesartan and 46.8 to 48.3 ml/mint/1.73 m2 in those with enalapril and remained unchanged at the end of the study.
gold	Enalapril	Olmesartan	Microalbuminuria decrease	The decreases in microalbuminuria were also similar (23% in olmesartan and 29% in enalapril patients)
x	enalapril	olmesartan	microalbuminuria	The decreases in microalbuminuria were also similar (23% in olmesartan and 29% in enalapril patients) in the 4 weeks time point.
gold	Enalapril	Olmesartan	Urinary potassium	Furthermore, among those terminating the study there were no significant differences in urinary potassium with respect to baseline values (79.6 ± 9.4 vs. 81.1 ± 8.1 mmol/L for olmesartan and 81.7 ± 15.2 vs. 62.7 ± 6.5 mmol/L for enalapril) or appreciable changes in daily urine sodium elimination.
x	enalapril	olmesartan	daily urine sodium elimination .	Furthermore, among those terminating the study there were no significant differences in urinary potassium with respect to baseline values (79.6 ± 9.4 vs. 81.1 ± 8.1 mmol/L for olmesartan and 81.7 ± 15.2 vs. 62.7 ± 6.5 mmol/L for enalapril) or appreciable changes in daily urine sodium elimination.
gold	Enalapril	Olmesartan	Urinary potassium	Furthermore, among those terminating the study there were no significant differences in urinary potassium with respect to baseline values (79.6 ± 9.4 vs. 81.1 ± 8.1 mmol/L for olmesartan and 81.7 ± 15.2 vs. 62.7 ± 6.5 mmol/L for enalapril) or appreciable changes in daily urine sodium elimination.
x	enalapril	olmesartan	urinary potassium	Furthermore, among those terminating the study there were no significant differences in urinary potassium with respect to baseline values (79.6 ± 9.4 vs. 81.1 ± 8.1 mmol/L for olmesartan and 81.7 ± 15.2 vs. 62.7 ± 6.5 mmol/L for enalapril) or appreciable changes in daily urine sodium elimination.
gold	Glycopyrronium bromide 12.5 μg OD	Placebo	FEV1	increases in mean trough FEV1 versus placebo were statistically significant for all regimens, ranging from 51 mL (glycopyrronium bromide 12.5 μg OD) to 160 mL (glycopyrronium bromide 50 μg BID).
x	glycopyrronium bromide	placebo	bronchodilation	All OD and BID dosing regimens produced dose-dependent bronchodilation; at Day 28, increases in mean trough FEV1 versus placebo were statistically significant for all regimens, ranging from 51 mL (glycopyrronium bromide 12.5 μg OD) to 160 mL (glycopyrronium bromide 50 μg BID).
gold	Glycopyrronium bromide 12.5 μg OD	Placebo	FEV1	increases in mean trough FEV1 versus placebo were statistically significant for all regimens, ranging from 51 mL (glycopyrronium bromide 12.5 μg OD) to 160 mL (glycopyrronium bromide 50 μg BID).
x	glycopyrronium bromide	placebo	mean trough FEV1	All OD and BID dosing regimens produced dose-dependent bronchodilation; at Day 28, increases in mean trough FEV1 versus placebo were statistically significant for all regimens, ranging from 51 mL (glycopyrronium bromide 12.5 μg OD) to 160 mL (glycopyrronium bromide 50 μg BID).
gold	Glycopyrronium bromide 100 μg OD	Placebo	FEV1	Furthermore, all glycopyrronium bromide treatment groups had statistically significant absolute increases in mean trough FEV1 compared with placebo.
x	glycopyrronium bromide	placebo	mean trough FEV1	Furthermore, all glycopyrronium bromide treatment groups had statistically significant absolute increases in mean trough FEV1 compared with placebo.
gold	Glycopyrronium bromide 100 μg OD	Placebo	FEV1	Dose–response results for FEV1 at 12 hours, FEV1 AUC0-12h and FEV1 AUC0-4h at steady-state showed OD regimens provided greater improvement over placebo than BID regimens for total daily doses of 25 μg, 50 μg and 100 μg,
c	placebo	OD dosing	FEV1	Dose–response results for FEV1 at 12 hours, FEV1 AUC0-12h and FEV1 AUC0-4h at steady-state showed OD regimens provided greater improvement over placebo than BID regimens for total daily doses of 25 μg, 50 μg and 100 μg, while the reverse was true for OD versus BID regimens from 12–24 hours.
gold	Glycopyrronium bromide 100 μg OD	Placebo	FEV1	Dose–response results for FEV1 at 12 hours, FEV1 AUC0-12h and FEV1 AUC0-4h at steady-state showed OD regimens provided greater improvement over placebo than BID regimens for total daily doses of 25 μg, 50 μg and 100 μg,
c	placebo	OD dosing	FEV1 AUC0	Dose–response results for FEV1 at 12 hours, FEV1 AUC0-12h and FEV1 AUC0-4h at steady-state showed OD regimens provided greater improvement over placebo than BID regimens for total daily doses of 25 μg, 50 μg and 100 μg, while the reverse was true for OD versus BID regimens from 12–24 hours.
gold	NSI-189 	Placebo	Overall hippocampal volume after 28 days	Analysis of covariance results did not show significant differences in hippocampal volume at day 28 (left: F(1,21)=0.06, P=0.80; right: F(1,21)=0.71, P=0.41)
c	placebo	NSI - 189	hippocampal volume	Analysis of covariance results did not show significant differences in hippocampal volume at day 28 (left: F(1,21)=0.06, P=0.80; right: F(1,21)=0.71, P=0.41) or day 84 (left: F(1,18)=1.25, P=0.28; right: F(1,18)=4.17, P=0.06) between the pooled NSI-189 and placebo-treated patients.
gold	NSI-189	Placebo	Left hippocampal volume after 28 days	The post hoc repeated measures analysis of variance suggested a modest but not statistically significant increase in the left hippocampal volume in the NSI-189-treated patients (b=0.35, P=0.12), but not the right side (right: b=−0.03, P=0.82).
c	NSI - 189	NSI - 189	left hippocampal volume	The post hoc repeated measures analysis of variance suggested a modest but not statistically significant increase in the left hippocampal volume in the NSI-189-treated patients (b=0.35, P=0.12), but not the right side (right: b=−0.03, P=0.82).
